[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 484
1. Chamberlain MC, Tsao-Wei DD, Groshen S: Salvage chemotherapy with cyclophosphamide for recurrent temozolomide-refractory anaplastic astrocytoma. Cancer; 2006 Jan 1;106(1):172-9
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage chemotherapy with cyclophosphamide for recurrent temozolomide-refractory anaplastic astrocytoma.
  • BACKGROUND: A prospective Phase II study of cyclophosphamide (CYC) was conducted in adult patients with recurrent temozolomide-refractory anaplastic astrocytoma (AA) with a primary objective of evaluating 6-month progression-free survival (PFS).
  • CONCLUSIONS: CYC demonstrated modest efficacy with acceptable toxicity in this cohort of adult patients with recurrent anaplastic astrocytoma, all of whom had failed prior TMZ chemotherapy.
  • [MeSH-major] Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Cyclophosphamide / therapeutic use. Dacarbazine / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy. Salvage Therapy

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 16323194.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


2. Chamberlain MC, Wei-Tsao DD, Blumenthal DT, Glantz MJ: Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory anaplastic astrocytoma. Cancer; 2008 May 1;112(9):2038-45
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory anaplastic astrocytoma.
  • BACKGROUND: The primary objective of this prospective phase 2 study of CPT-11 in adult patients with recurrent temozolomide-refractory anaplastic astrocytoma (AA) was to evaluate 6-month progression-free survival (PFS).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Camptothecin / analogs & derivatives. Dacarbazine / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy. Salvage Therapy / methods

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18361434.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 7673326042 / irinotecan; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


3. Tanaka K, Sasayama T, Kawamura A, Kondoh T, Kanomata N, Kohmura E: Isolated oculomotor nerve paresis in anaplastic astrocytoma with exophytic invasion. Neurol Med Chir (Tokyo); 2006 Apr;46(4):198-201
Genetic Alliance. consumer health - Anaplastic Astrocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated oculomotor nerve paresis in anaplastic astrocytoma with exophytic invasion.
  • The histological diagnosis was anaplastic astrocytoma.
  • Malignant glioma with exophytic growth in the temporal lobe should be considered in the differential diagnosis of isolated oculomotor nerve paresis.
  • [MeSH-major] Astrocytoma / complications. Oculomotor Nerve Diseases / etiology. Supratentorial Neoplasms / complications. Temporal Lobe
  • [MeSH-minor] Adult. Astrocytes / pathology. Biomarkers, Tumor / analysis. Brain Stem / pathology. Cerebral Arteries / pathology. Cisterna Magna / pathology. Dominance, Cerebral / physiology. Humans. Image Processing, Computer-Assisted. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness / pathology. Nerve Compression Syndromes / diagnosis. Nerve Compression Syndromes / etiology. Nerve Compression Syndromes / pathology. Nerve Compression Syndromes / surgery. Neuronavigation. Oculomotor Nerve / pathology. Oculomotor Nerve / surgery. Pons / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16636512.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


Advertisement
4. Gupta B, Raina J: Fascicular multiple ocular motor nerve paresis as first presentation of anaplastic astrocytoma. Indian J Ophthalmol; 2007 Nov-Dec;55(6):458-60
Genetic Alliance. consumer health - Anaplastic Astrocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fascicular multiple ocular motor nerve paresis as first presentation of anaplastic astrocytoma.
  • A case of spontaneous, painless partial III (pupil-sparing) and IV fascicular nerve paresis as the first presentation of anaplastic astrocytoma is reported.
  • [MeSH-major] Astrocytoma / complications. Brain Stem Neoplasms / complications. Oculomotor Nerve Diseases / etiology
  • [MeSH-minor] Adult. Biopsy. Diagnosis, Differential. Eye Movements. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiologe. 1999 Oct;39(10):821-7 [10550380.001]
  • [Cites] Acta Neurochir (Wien). 1979;49(1-2):35-45 [230705.001]
  • [Cites] J Clin Neurosci. 2005 Nov;12(8):946-9 [16326274.001]
  • [Cites] Neurol Neurochir Pol. 1983 Jul-Aug;17(4):471-5 [6646330.001]
  • [Cites] Neurosurgery. 1982 Apr;10(4):437-44 [7099393.001]
  • (PMID = 17951905.001).
  • [ISSN] 0301-4738
  • [Journal-full-title] Indian journal of ophthalmology
  • [ISO-abbreviation] Indian J Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2635986
  •  go-up   go-down


5. Anselmo NP, Rey JA, Almeida LO, Custódio AC, Almeida JR, Clara CA, Santos MJ, Casartelli C: Concurrent sequence variation of TP53 and TP73 genes in anaplastic astrocytoma. Genet Mol Res; 2009;8(4):1257-63
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent sequence variation of TP53 and TP73 genes in anaplastic astrocytoma.
  • Using PCR-SSCP and gene sequencing, we analyzed the TP53 and TP73 genes in a case of a grade III anaplastic astrocytoma that progressed to glioblastoma.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. DNA-Binding Proteins / genetics. Nuclear Proteins / genetics. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19876867.001).
  • [ISSN] 1676-5680
  • [Journal-full-title] Genetics and molecular research : GMR
  • [ISO-abbreviation] Genet. Mol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; 0 / tumor suppressor protein p73
  •  go-up   go-down


6. Dreyfuss JM, Johnson MD, Park PJ: Meta-analysis of glioblastoma multiforme versus anaplastic astrocytoma identifies robust gene markers. Mol Cancer; 2009 Sep 04;8:71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meta-analysis of glioblastoma multiforme versus anaplastic astrocytoma identifies robust gene markers.
  • BACKGROUND: Anaplastic astrocytoma (AA) and its more aggressive counterpart, glioblastoma multiforme (GBM), are the most common intrinsic brain tumors in adults and are almost universally fatal.
  • A deeper understanding of the molecular relationship of these tumor types is necessary to derive insights into the diagnosis, prognosis, and treatment of gliomas.
  • These feature lists could be utilized to aid in diagnosis, prognosis, and grade reduction of high-grade gliomas and to identify genes that were not previously suspected of playing an important role in glioma biology.

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1999 Dec;81(8):1371-7 [10604735.001]
  • [Cites] Mol Endocrinol. 2000 Jun;14(6):848-62 [10847587.001]
  • [Cites] J Biol Chem. 2000 Jul 7;275(27):20315-23 [10783396.001]
  • [Cites] BMC Bioinformatics. 2008;9:63 [18226260.001]
  • [Cites] Genomics. 2008 May;91(5):395-406 [18343632.001]
  • [Cites] Mol Cancer Ther. 2008 May;7(5):1013-24 [18445660.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Sep 5;373(4):539-44 [18590702.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1061-8 [18772890.001]
  • [Cites] BMC Bioinformatics. 2009;10:1 [19118496.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):31-6 [11134512.001]
  • [Cites] FASEB J. 2001 Feb;15(2):458-66 [11156961.001]
  • [Cites] Am J Pathol. 2002 Apr;160(4):1279-92 [11943713.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4427-33 [12154050.001]
  • [Cites] Am J Pathol. 2002 Nov;161(5):1695-700 [12414516.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6205-10 [12414648.001]
  • [Cites] Acta Neuropathol. 2003 Jan;105(1):49-57 [12471461.001]
  • [Cites] Pancreas. 2003 Jan;26(1):56-64 [12499918.001]
  • [Cites] Nucleic Acids Res. 2003 Feb 15;31(4):e15 [12582260.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):1138-43 [12615733.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1602-7 [12670911.001]
  • [Cites] Oncogene. 2003 Apr 17;22(15):2361-73 [12700671.001]
  • [Cites] Genome Biol. 2003;4(4):210 [12702200.001]
  • [Cites] Nat Genet. 2003 Jul;34(3):267-73 [12808457.001]
  • [Cites] Bioinformatics. 2003;19 Suppl 1:i84-90 [12855442.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9440-5 [12883005.001]
  • [Cites] Surg Neurol. 2003 Nov;60(5):402-6; discussion 406 [14572960.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):212-21 [14734472.001]
  • [Cites] Bioinformatics. 2004 Feb 12;20(3):307-15 [14960456.001]
  • [Cites] Nat Biotechnol. 2004 May;22(5):615-21 [15122300.001]
  • [Cites] FEBS Lett. 2004 Aug 27;573(1-3):83-92 [15327980.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6503-10 [15374961.001]
  • [Cites] Genome Biol. 2004;5(10):R80 [15461798.001]
  • [Cites] Mol Cell Biol. 1996 Sep;16(9):4604-13 [8756616.001]
  • [Cites] J Biol Chem. 1996 Dec 20;271(51):32529-37 [8955077.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):895-900 [10029081.001]
  • [Cites] Cancer Res. 1999 Aug 15;59(16):3915-8 [10463582.001]
  • [Cites] BMC Bioinformatics. 2004 Oct 25;5:159 [15504239.001]
  • [Cites] Bioinformatics. 2004 Nov 22;20(17):3166-78 [15231529.001]
  • [Cites] Genome Biol. 2005;6(2):R16 [15693945.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1678-86 [15753362.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3326-34 [15867231.001]
  • [Cites] Nat Methods. 2005 May;2(5):345-50 [15846361.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13544-9 [16174746.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]
  • [Cites] J Bioinform Comput Biol. 2005 Oct;3(5):1171-89 [16278953.001]
  • [Cites] Nat Rev Genet. 2006 Jan;7(1):55-65 [16369572.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):159-67 [16397228.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):157-73 [16530701.001]
  • [Cites] Cancer Cell. 2006 Apr;9(4):287-300 [16616334.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):233-47 [16612574.001]
  • [Cites] Biom J. 2006 Jun;48(3):435-50 [16845907.001]
  • [Cites] BMC Bioinformatics. 2006;7:359 [16872483.001]
  • [Cites] Nucleic Acids Res. 2007 Jan;35(Database issue):D760-5 [17099226.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1445-53 [17456751.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 10;104(28):11736-41 [17606927.001]
  • [Cites] Cancer Res. 2007 Nov 1;67(21):10296-303 [17974971.001]
  • [Cites] Neurosurg Rev. 2008 Jan;31(1):83-9; discussion 89-90 [17917751.001]
  • [Cites] Comput Biol Chem. 2008 Feb;32(1):38-46 [17988949.001]
  • [Cites] Bioinformatics. 2008 Feb 1;24(3):374-82 [18204063.001]
  • [Cites] Ann Vasc Surg. 2008 Mar;22(2):273-84 [18346582.001]
  • (PMID = 19732454.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM082798; United States / NIH HHS / OD / DP2 OD002319; United States / NIH HHS / OD / DP2OD002319; United States / NLM NIH HHS / LM / U54 LM008748; United States / NLM NIH HHS / LM / U54LM008748
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ PMC2743637
  •  go-up   go-down


7. Azad A, Deb S, Cher L: Primary anaplastic pilocytic astrocytoma. J Clin Neurosci; 2009 Dec;16(12):1704-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary anaplastic pilocytic astrocytoma.
  • We report two adult patients with pilocytic astrocytomas with anaplastic features at initial diagnosis.
  • Pilocytic astrocytomas are low-grade astrocytomas that occur rarely in adults.
  • Initial presentation of a pilocytic astrocytoma with anaplastic features is particularly uncommon and making a definitive diagnosis of pilocytic astrocytoma with anaplastic features can be challenging.
  • It is critical to differentiate glioblastoma (World Health Organization [WHO] grade 4) and pilocytic astrocytoma with anaplastic features (WHO grade 3) from pilocytic astrocytoma (WHO grade 1) as there are significant therapeutic and prognostic implications.
  • Improved therapeutic strategies are required for pilocytic astrocytomas with anaplastic features.
  • [MeSH-major] Anaplasia / complications. Astrocytoma / complications. Brain Neoplasms / complications

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19815416.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


8. Stupp R, Reni M, Gatta G, Mazza E, Vecht C: Anaplastic astrocytoma in adults. Crit Rev Oncol Hematol; 2007 Jul;63(1):72-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic astrocytoma in adults.
  • Anaplastic astrocytoma is an uncommon disease in the adult population.
  • Based on randomized data available, chemotherapy has consistently failed to improve the outcome of patients with anaplastic astrocytoma, while a meta-analysis showed a small, but significant improvement in survival favouring the use of chemotherapy.
  • In recurrent disease, chemotherapy with temozolomide has been proven to be active and well-tolerated in phase II trials, but no comparative phase III trials of other cytotoxic drugs have been conducted.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for anaplastic astrocytoma .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17478095.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  • [Number-of-references] 69
  •  go-up   go-down


9. Fernandez A, Karavitaki N, Ansorge O, Fazal-Sanderson V, Wass JA: Acromegaly and anaplastic astrocytoma: coincidence or pathophysiological relation? Pituitary; 2008;11(3):325-30
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acromegaly and anaplastic astrocytoma: coincidence or pathophysiological relation?
  • We report the case of a 28-year-old man who presented simultaneously with acromegaly and an anaplastic astrocytoma, which had rapidly progressed from a low-grade astrocytoma.
  • The coexistence of systemic IGF-I hypersecretion with a quick progression in the histopathological grade of the astrocytoma raises the compelling question of whether the clinical behavior of the astrocytic tumor was influenced by the acromegalic status.
  • [MeSH-major] Acromegaly / complications. Astrocytoma / complications. Brain Neoplasms / complications

  • Genetic Alliance. consumer health - Acromegaly.
  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18000757.001).
  • [ISSN] 1386-341X
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ergolines; 0 / Peptides, Cyclic; 118992-92-0 / lanreotide; 51110-01-1 / Somatostatin; 67763-96-6 / Insulin-Like Growth Factor I; LL60K9J05T / cabergoline
  •  go-up   go-down


10. Kumar R, Kamdar D, Madden L, Hills C, Crooks D, O'Brien D, Greenman J: Th1/Th2 cytokine imbalance in meningioma, anaplastic astrocytoma and glioblastoma multiforme patients. Oncol Rep; 2006 Jun;15(6):1513-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Th1/Th2 cytokine imbalance in meningioma, anaplastic astrocytoma and glioblastoma multiforme patients.
  • Serum samples from 61 newly diagnosed patients with brain tumours and 50 age- and sex-matched non-tumour controls were analysed by ELISA for circulating levels of interleukin-12 (IL-12p70 and p40) and interleukin-10 (IL-10); pivotal Th1 and Th2 cytokines, respectively.
  • Patients were divided into various groups depending on their histological diagnosis: meningioma (n=11), anaplastic astrocytoma (n=4) and glioblastoma multiforme (GBM; n=46).
  • Significant reduction in serum IL-12 was seen in all groups as compared with the controls: meningioma, p=0.03; anaplastic astrocytoma, p<0.001; and GBM, p<0.001.
  • Conversely, serum IL-10 was significantly increased in anaplastic astrocytoma, p=0.02, and GBM, p=0.03.
  • This study shows that patients with advanced primary intracranial malignancies have decreased circulating IL-12 and increased circulating IL-10, demonstrating that brain tumours have a major systemic effect on the immune system.
  • [MeSH-major] Astrocytoma / immunology. Brain Neoplasms / immunology. Glioblastoma / immunology. Interleukin-10 / blood. Interleukin-12 / blood. Meningioma / immunology. Th1 Cells / immunology. Th2 Cells / immunology


11. Arai Y, Tsuchida T, Tanioka F, Sugimura H, Watanabe C, Hongo T, Tsutsui Y: Congenital anaplastic astrocytoma differentiated into pilocytic astrocytoma: an autopsy case. Neuropathology; 2008 Aug;28(4):433-9
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Congenital anaplastic astrocytoma differentiated into pilocytic astrocytoma: an autopsy case.
  • We report an autopsy case of congenital astrocytoma and its histopathological changes during 5 years of the patient's development from birth to death.
  • The right orbital tumor, which was enucleated at 2 months of age, was a highly cellular tumor with moderate pleomorphism resembling anaplastic astrocytoma.
  • On the other hand, at autopsy, a brain tumor was found in the right diencephalic region with features of pilocytic astrocytoma, accompanied by leptomeningeal dissemination.
  • A biopsy specimen, which was obtained from the chiasmatic part of the tumor at 4 months of age, showed an intermediate appearance between the orbital tumor and the brain tumor obtained at autopsy.
  • We believe that this congenital anaplastic astrocytoma differentiated into a pilocytic astrocytoma during the 5 years of the patient's development.
  • The transformation of the congenital astrocytoma from anaplastic to pilocytic forms can be attributed to the nature of the tumor, namely postmitotic neoplastic cells are characterized by their ability to undergo self-differentiation, along with the organotropism of the developing brain.
  • [MeSH-major] Astrocytoma / congenital. Astrocytoma / pathology. Brain Neoplasms / congenital. Brain Neoplasms / pathology


12. Kinjo S, Yokoo H, Hirato J, Nakazato Y: Anaplastic astrocytoma with eosinophilic granular cells. Neuropathology; 2007 Oct;27(5):457-62
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic astrocytoma with eosinophilic granular cells.
  • Thus, the tumor was histologically diagnosed as anaplastic astrocytoma.
  • The present case should also be discriminated from granular cell astrocytoma.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18018480.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


13. Chamberlain MC, Johnston S: Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma. J Neurooncol; 2009 Feb;91(3):359-67
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma.
  • A retrospective study of bevacizumab only in adults with recurrent temozolomide (TMZ)-refractory anaplastic astrocytoma (AA) with a primary objective of determining progression free survival (PFS).
  • Bevacizumab-related toxicity included fatigue (14 patients; 2 grade 3), leukopenia (7; 1 grade 3), deep vein thrombosis (5; 2 grade 3), hypertension (5; 1 grade 3), anemia (4; 0 grade 3) and wound dehiscence (1; 1 grade 3).
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Astrocytoma / drug therapy. Astrocytoma / mortality. Brain Neoplasms / drug therapy. Brain Neoplasms / mortality. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18953491.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


14. Shibahara I, Kanamori M, Kumabe T, Endo H, Sonoda Y, Ogawa Y, Watanabe M, Tominaga T: Hemorrhagic onset of pilocytic astrocytoma and pilomyxoid astrocytoma. Brain Tumor Pathol; 2009;26(1):1-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hemorrhagic onset of pilocytic astrocytoma and pilomyxoid astrocytoma.
  • The incidence of hemorrhagic onset in pilocytic astrocytoma and pilomyxoid astrocytoma, and the clinical and histological characteristics, were compared to other types of neuroepithelial tumors or nonhemorrhagic pilocytic astrocytoma by retrospective review of 445 consecutive neuroepithelial tumors treated at our institute.
  • Hemorrhagic onset was observed in 4 of 35 (11.4%) patients with pilocytic astrocytoma and pilomyxoid astrocytoma, with higher incidence than in glioblastoma (3.9%), anaplastic oligodendroglioma (7.7%), and anaplastic ependymoma (7.1%).
  • The hemorrhagic onset occurred in 2 patients with sporadic pilocytic astrocytoma, 1 with pilocytic astrocytoma associated with neurofibromatosis type 1, and 1 with pilomyxoid astrocytoma.
  • Hemorrhagic onset of pilocytic astrocytoma and pilomyxoid astrocytoma is not as uncommon as was previously thought, so pilocytic astrocytoma or pilomyxoid astrocytoma should be considered in the differential diagnosis of patients with brain tumors manifesting as hemorrhagic onset.
  • [MeSH-major] Astrocytoma / complications. Astrocytoma / pathology. Brain Neoplasms / complications. Brain Neoplasms / pathology. Intracranial Hemorrhages / etiology. Intracranial Hemorrhages / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Brain / pathology. Capillaries / pathology. Child. Child, Preschool. Female. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Magnetic Resonance Imaging. Male. Middle Aged. Neurofibromatosis 1 / complications. Neurofibromatosis 1 / pathology. Paralysis / etiology. Tomography, X-Ray Computed. Young Adult

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19408090.001).
  • [ISSN] 1861-387X
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


15. Khongkhatithum C, Visudtibhan A, Chiemchanya S, Visudhiphan P, Sanvivad P, Larbcharoensub N, Phudhicharoenrat S: Multicentric anaplastic astrocytoma in a child. J Clin Neurosci; 2007 Feb;14(2):176-9
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentric anaplastic astrocytoma in a child.
  • We report a rare case of anaplastic astrocytoma with multicentric central nervous system lesions in a 10-year-old girl presenting with a 1-month history of progressive headache and paraparesis.
  • Neurological examination upon admission revealed papilloedema of both eyes and grade 2/5 weakness of both legs.
  • The histological diagnosis was anaplastic astrocytoma based on the WHO classification.
  • Despite being an uncommon disease in children and being associated with an unfavourable long-term outcome, early diagnosis and appropriate management of this condition may contribute to reduced patient morbidity.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Spinal Cord Neoplasms / pathology

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17161293.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


16. Yoshida T, Niwa F, Kimura S, Nakagawa M: Anaplastic astrocytoma presenting as reversible posterior leukoencephalopathy syndrome. Neurologist; 2006 Nov;12(6):311-3
MedlinePlus Health Information. consumer health - Brain Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic astrocytoma presenting as reversible posterior leukoencephalopathy syndrome.
  • We report a 60-year-old man with grade III astrocytoma, who presented with status epilepticus.
  • The initial MRI did not demonstrate typical findings of an astrocytoma but rather showed reversible posterior leukoencephalopathy syndrome (RPLS).
  • A brain tumor should be considered and the patient carefully followed by MRI, even if the MRI white matter lesion pattern suggests RPLS.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Diseases / diagnosis. Occipital Lobe / pathology

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17122727.001).
  • [ISSN] 1074-7931
  • [Journal-full-title] The neurologist
  • [ISO-abbreviation] Neurologist
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Brehar FM, Ciurea AV, Zarnescu O, Bleotu C, Gorgan RM, Dragu D, Matei L: Infiltrating growing pattern xenografts induced by glioblastoma and anaplastic astrocytoma derived tumor stem cells. Chirurgia (Bucur); 2010 Sep-Oct;105(5):685-94
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infiltrating growing pattern xenografts induced by glioblastoma and anaplastic astrocytoma derived tumor stem cells.
  • OBJECTIVE: The number of evidences regarding the role of tumor stem cells (TSC) in the initiation and progression of high-grade astrocytomas became more and more numerous in the last years.
  • This issue has been intensively tested in glioblastoma, but little attention has been paid for anaplastic astrocytoma.
  • The main objective of this paper was to study the morphological characteristics of the xenografts developed from glioblastoma and anaplastic astrocytoma derived cancer stem cells.
  • METHODS: The authors of this study successfully isolated and partial characterized primary cultures of glioblastoma and anaplastic astrocytoma derived TSC.
  • RESULTS: The tumor xenografts which have been established in nude mice using TSC had different characteristics when compared with U87 xenografts previously developed by our group, and depend of the origin type of the tumors (glioblastoma versus anaplastic astrocytoma).
  • The diffuse growing pattern and cells infiltration have been more pronounced in both anaplastic astrocytoma and glioblastoma derived TSC xenografts compared with U87 line xenografts.
  • CONCLUSION: Our results support the hypothesis regarding the role of TSC in the infiltration process of glioblastoma and anaplastic astrocytoma.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Glioblastoma / pathology. Neoplastic Stem Cells / pathology. Transplantation, Heterologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21141095.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Romania
  •  go-up   go-down


18. Hope AJ, Mansur DB, Tu PH, Simpson JR: Metachronous secondary atypical meningioma and anaplastic astrocytoma after postoperative craniospinal irradiation for medulloblastoma. Childs Nerv Syst; 2006 Sep;22(9):1201-7
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metachronous secondary atypical meningioma and anaplastic astrocytoma after postoperative craniospinal irradiation for medulloblastoma.
  • INTRODUCTION: Malignant brain tumors have been reported to occur after childhood irradiation more frequently than in the nonirradiated population.
  • DISCUSSION: In this study, we report the case of a 15-year-old boy treated for medulloblastoma with surgery and craniospinal radiotherapy, who developed a meningioma 18 years after initial treatment and subsequently an anaplastic astrocytoma 23 years after primary treatment.
  • The patient is currently alive but with recurrent astrocytoma after a complete remission on temozolomide monotherapy.
  • [MeSH-major] Astrocytoma / diagnosis. Cerebellar Neoplasms / radiotherapy. Cranial Irradiation / adverse effects. Medulloblastoma / radiotherapy. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis. Neoplasms, Radiation-Induced / diagnosis. Neoplasms, Second Primary / diagnosis

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1987 Dec;67(6):915-8 [2824720.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3761-7 [9850019.001]
  • [Cites] J Neurosurg. 1989 Mar;70(3):469-74 [2536806.001]
  • [Cites] Ann Neurol. 1978 Oct;4(4):319-21 [727737.001]
  • [Cites] Childs Nerv Syst. 2000 Jul;16(7):390-7 [10958546.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):618-29 [11309438.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):65-73 [10924973.001]
  • [Cites] Childs Nerv Syst. 2004 Apr;20(4):243-6 [14704813.001]
  • [Cites] Cancer. 1984 Feb 1;53(3):426-9 [6581853.001]
  • [Cites] Lancet. 1997 May 10;349(9062):1369 [9149706.001]
  • [Cites] J Pediatr Endocrinol Metab. 2003 Jan;16(1):97-101 [12585346.001]
  • [Cites] Surg Neurol. 2003 Jul;60(1):60-7; discussion 67 [12865017.001]
  • [Cites] Clin Neuropathol. 1994 Sep-Oct;13(5):281-5 [7805312.001]
  • [Cites] Cancer. 1998 Jan 1;82(1):8-34 [9428476.001]
  • [Cites] Pediatr Neurosurg. 1996 Oct;25(4):214-9 [9293548.001]
  • [Cites] J Neurosurg. 1998 Jan;88(1):111-5 [9420081.001]
  • [Cites] J Neurosurg. 1978 Apr;48(4):622-7 [632887.001]
  • [Cites] BMJ. 1993 Oct 23;307(6911):1030-6 [8251777.001]
  • [Cites] N Engl J Med. 1988 Oct 20;319(16):1033-9 [3173432.001]
  • [Cites] Cancer Causes Control. 1997 Nov;8(6):865-71 [9427429.001]
  • [Cites] Neurosurgery. 1995 Apr;36(4):685-90 [7596497.001]
  • [Cites] N Engl J Med. 1995 Mar 30;332(13):839-47 [7661930.001]
  • [Cites] Acta Neurochir (Wien). 2001;143(7):697-700 [11534690.001]
  • [Cites] J Neuroradiol. 1983;10 (1):43-9 [6864263.001]
  • [Cites] Neurology. 1981 May;31(5):616-9 [7194977.001]
  • [Cites] Neurosurgery. 1980 May;6(5):546-51 [6251397.001]
  • [Cites] Lancet. 1974 Feb 23;1(7852):277-9 [4130470.001]
  • [Cites] J Neurosurg. 1995 Jul;83(1):154-62 [7782835.001]
  • [Cites] Clin Neurol Neurosurg. 1998 Mar;100(1):56-9 [9637208.001]
  • [Cites] Can J Neurol Sci. 1984 Nov;11(4):475-8 [6518432.001]
  • [Cites] Arch Ophthalmol. 1988 Dec;106(12 ):1701-5 [3196211.001]
  • [Cites] Cancer. 1999 Jan 15;85(2):485-91 [10023719.001]
  • [Cites] Onkologie. 2001 Feb;24(1):66-72 [11441284.001]
  • [Cites] Eur J Paediatr Neurol. 1999;3(4):177-80 [10476368.001]
  • [Cites] Can J Neurol Sci. 1992 Nov;19(4):498-503 [1330262.001]
  • [Cites] J Neurosurg. 1978 Sep;49(3):445-9 [682008.001]
  • [Cites] Am J Public Health Nations Health. 1966 Dec;56(12):2114-20 [5334312.001]
  • [Cites] Cancer. 1979 Jan;43(1):129-36 [104784.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Oct;23(7):431-6 [11878577.001]
  • (PMID = 16570196.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 40
  •  go-up   go-down


19. Yue WY, Chen ZP: Does vasculogenic mimicry exist in astrocytoma? J Histochem Cytochem; 2005 Aug;53(8):997-1002
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does vasculogenic mimicry exist in astrocytoma?
  • It is unknown whether a similar VM phenomenon exists in astrocytoma.
  • The present study was to examine 45 astrocytomas (including World Health Organization grade II 15 cases, grade III 15 cases, and grade IV 15 cases) by CD34 endothelial marker periodic acid-Schiff (PAS) dual staining to see if VM existing in these tumors.
  • PAS-positive pattern of VM was found in two grade IV astrocytomas.
  • Furthermore, in astrocytoma, especially glioblastoma, focus of anaplastic tumor cells appeared with CD34 expression, whereas some tumor cells lost glial fibrillary acid protein expression.
  • It is assumed that genetically deregulated tumor cells in astrocytoma could lose the astrocyte-specific protein and express inappropriate markers not expected in cells of astrocyte lineage.
  • The present results suggest that VM phenomenon exists in some malignant astrocytoma.
  • [MeSH-major] Astrocytoma / blood supply. Brain Neoplasms / blood supply

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15923371.001).
  • [ISSN] 0022-1554
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers; 0 / Coloring Agents; 0 / Schiff Bases; 10450-60-9 / Periodic Acid
  •  go-up   go-down


20. Fountaine T, Lind CR, Law AJ: Primary glioblastomas and anaplastic astrocytoma in a glioma family. J Clin Neurosci; 2006 May;13(4):497-501
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary glioblastomas and anaplastic astrocytoma in a glioma family.
  • A 72-year-old man presented with a short duration of symptoms relating to a right fronto-parietal glioblastoma and a family history of children with brain tumours.
  • Analysis of the patient's family tree revealed that out of seven children, he had a living son with anaplastic astrocytoma, a daughter who had died with a glioblastoma, and a son who had died with a histologically undiagnosed intrinsic brain tumour.
  • One niece was also thought to have died from a brain tumour.
  • There is no clinical evidence to support a diagnosis of a multiple cancer or neurocutaneous syndrome in this family.
  • In view of what is known about the genetics of familial glioma, it is interesting to note the clinical evidence of both 'primary' glioblastoma and anaplastic astrocytoma in the same kindred.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Family Health. Glioblastoma / genetics

  • Genetic Alliance. consumer health - Glioma.
  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16678736.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


21. van den Bent MJ: Anaplastic oligodendroglioma and oligoastrocytoma. Neurol Clin; 2007 Nov;25(4):1089-109, ix-x
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic oligodendroglioma and oligoastrocytoma.
  • Until approximately 15 years ago, the diagnosis of an oligodendroglioma (OD) was merely as a pathologic entity.
  • The only clinical relevant meaning of this histologic diagnosis was the observation that the prognosis of OD was in general better than that of astrocytic tumors of similar grade.
  • Observations have led to the current tendency to consider 1p/19q loss low-grade and anaplastic oligodendroglioma a separate biologic entity, at least within clinical trials, since they have a much better outcome.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Oligodendroglioma / pathology


22. Ooba H, Abe T, Kamida T, Anan M, Momii Y, Tokuuye K, Fujiki M: Malignant fibrous histiocytosis after high-dose proton radiation therapy for anaplastic astrocytoma. J Clin Neurosci; 2009 Dec;16(12):1641-3
Genetic Alliance. consumer health - Anaplastic Astrocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytosis after high-dose proton radiation therapy for anaplastic astrocytoma.
  • This report presents a 70-year-old male who presented with a rare malignant fibrous histiocytosis after high-dose proton radiation therapy for anaplastic astrocytoma.
  • [MeSH-minor] Aged. Astrocytoma / radiotherapy. Brain Neoplasms / radiotherapy. Humans. Magnetic Resonance Imaging / methods. Male

  • Genetic Alliance. consumer health - Histiocytosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19766005.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


23. Wacker A, Will BE, Schöning M, Neunhoeffer F: [Intracerebral bleeding as the first symptom of a congenital anaplastic astrocytoma]. Z Geburtshilfe Neonatol; 2008 Oct;212(5):194-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intracerebral bleeding as the first symptom of a congenital anaplastic astrocytoma].
  • BACKGROUND: Anaplastic astrocytomas in neonates are extremely rare.
  • An ultrasound scan of the brain showed an intracerebral bleeding.
  • No tumour was found, but an anaplastic astrocytoma (WHO Grade III) was diagnosed histologically.
  • Serial ultrasound investigations of the brain showed a normal midline and a redevelopment of the left-sided ventricle.
  • CONCLUSION: Congenital anaplastic astrocytomas have a variable outcome, with different survival rates as compared to adults.
  • [MeSH-major] Astrocytoma / congenital. Brain Neoplasms / congenital. Cerebral Hemorrhage / congenital
  • [MeSH-minor] Diagnosis, Differential. Echoencephalography. Fatal Outcome. Female. Humans. Infant, Newborn. Magnetic Resonance Imaging. Occipital Lobe / pathology. Temporal Lobe / pathology. Tomography, X-Ray Computed. Trephining

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18956278.001).
  • [ISSN] 0948-2393
  • [Journal-full-title] Zeitschrift für Geburtshilfe und Neonatologie
  • [ISO-abbreviation] Z Geburtshilfe Neonatol
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


24. Nomiya T, Nemoto K, Kumabe T, Takai Y, Yamada S: Prognostic significance of surgery and radiation therapy in cases of anaplastic astrocytoma: retrospective analysis of 170 cases. J Neurosurg; 2007 Apr;106(4):575-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of surgery and radiation therapy in cases of anaplastic astrocytoma: retrospective analysis of 170 cases.
  • OBJECT: The purpose of this retrospective study was to estimate the prognostic impact of treatment parameters for 170 patients with anaplastic astrocytoma (AA).
  • [MeSH-major] Astrocytoma / radiotherapy. Astrocytoma / surgery. Brain Neoplasms / radiotherapy. Brain Neoplasms / surgery

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17432706.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Walid MS, Troup EC: Cerebellar anaplastic astrocytoma in a teenager with Ollier Disease. J Neurooncol; 2008 Aug;89(1):59-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebellar anaplastic astrocytoma in a teenager with Ollier Disease.
  • INTRODUCTION: Ollier Disease is a sporadic skeletal disorder with a predisposition to oncogenesis.
  • We are presenting a young patient with Ollier Disease and high-grade astrocytoma.
  • Brain MRI with contrast showed a 41 x 55 mm mass in the posterior fossa with spotty enhancement, which pathology proved to be anaplastic astrocytoma.
  • [MeSH-major] Astrocytoma / etiology. Astrocytoma / pathology. Cerebellar Neoplasms / etiology. Cerebellar Neoplasms / pathology. Cerebellum / pathology. Enchondromatosis / complications

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • Genetic Alliance. consumer health - Ollier disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18414790.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / PTH1R protein, human; 0 / Receptor, Parathyroid Hormone, Type 1; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


26. Korshunov A, Meyer J, Capper D, Christians A, Remke M, Witt H, Pfister S, von Deimling A, Hartmann C: Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol; 2009 Sep;118(3):401-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma.
  • Separation of pilocytic astrocytoma from diffuse astrocytomas frequently poses problems mostly related to small sample size.
  • Precise classification and grading are essential due to different therapeutic strategies prompted by diagnoses of pilocytic astrocytoma WHO grade I, diffuse astrocytomas WHO grade II or anaplastic astrocytoma WHO grade III.
  • We examined a series of 120 astrocytomas including 70 pilocytic astrocytomas WHO grade I and 50 diffuse astrocytomas WHO grade II for both, BRAF-KIAA1549 fusion with a newly developed FISH assay and mutations in IDH1 and IDH2 by direct sequencing.
  • Astrocytomas WHO grade II exhibited IDH1 mutations in 38 cases (76%) but neither IDH2 mutations nor BRAF fusions.
  • Thus, combined molecular analysis of BRAF and IDH1 is a sensitive and highly specific approach to separate pilocytic astrocytoma from diffuse astrocytoma.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Isocitrate Dehydrogenase / genetics. Proto-Oncogene Proteins B-raf / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Mutation. Tissue Array Analysis


27. Kanamori M, Kumabe T, Watanabe M, Tominaga T: Anaplastic astrocytoma and anaplastic oligodendroglioma occurring 6 years after subtotal resection of a central neurocytoma. Case report. J Neurosurg; 2007 Jul;107(1):185-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic astrocytoma and anaplastic oligodendroglioma occurring 6 years after subtotal resection of a central neurocytoma. Case report.
  • The authors present the case of a 51-year-old man who presented with an anaplastic astrocytoma and anaplastic oligodendroglioma that developed 6 years after subtotal resection of a central neurocytoma in his right lateral ventricle.
  • Histological examination revealed anaplastic oligodendroglioma in the parietal lobe and anaplastic astrocytoma in the insula.
  • One year later, the anaplastic astrocytoma was found to have transformed into a glioblastoma multiforme.
  • Fluorescence in situ hybridization analysis and immunohistochemical examinations detected deletions of the lp36 and 19q13 loci, and nuclear accumulation of TP53 protein in the anaplastic oligodendroglioma but not in the glioblastoma multiforme.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Neurocytoma / surgery. Oligodendroglioma / pathology


28. Compostella A, Tosoni A, Blatt V, Franceschi E, Brandes AA: Prognostic factors for anaplastic astrocytomas. J Neurooncol; 2007 Feb;81(3):295-303
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors for anaplastic astrocytomas.
  • Anaplastic astrocytomas (WHO grade III) constitute about 10% of all gliomas.
  • Currently, only few factors have been identified as useful for prognosis of anaplastic astrocytoma: age and Karnofsky Performance Status.
  • [MeSH-major] Astrocytoma / genetics. Astrocytoma / pathology. Biomarkers, Tumor / analysis. Brain Neoplasms / genetics. Brain Neoplasms / pathology


29. Matar E, Cook RJ, Fowler AR, Biggs MT, Little NS, Wheeler HR, Robinson BG, McDonald KL: Post-contrast enhancement as a clinical indicator of prognosis in patients with anaplastic astrocytoma. J Clin Neurosci; 2010 Aug;17(8):993-6
Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-contrast enhancement as a clinical indicator of prognosis in patients with anaplastic astrocytoma.
  • Diagnosis of an anaplastic astrocytoma (World Health Organization grade III) is associated with a highly variable prognosis.
  • In this study, we analysed 48 patients with a histological diagnosis of anaplastic astrocytoma and found peritumoral post-gadolinium contrast enhancement to be a clear prognostic marker of poor prognosis.
  • The survival differences observed in the enhancing and non-enhancing lesions in patients diagnosed with anaplastic astrocytoma supports the existence of a broad anaplastic spectrum of disease, with enhancement being a clinical marker of tumour progression along this spectrum.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Gadolinium. Image Enhancement

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20605464.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] AU0V1LM3JT / Gadolinium
  •  go-up   go-down


30. Volavsek M, Lamovec J, Popović M: Extraneural metastases of anaplastic oligodendroglial tumors. Pathol Res Pract; 2009;205(7):502-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraneural metastases of anaplastic oligodendroglial tumors.
  • According to the literature, they tend to appear in glioblastoma patients, but are exceptionally rare in anaplastic oligodendroglioma.
  • We report on an anaplastic oligodendroglioma and an anaplastic oligoastrocytoma that metastasized to cervical lymph nodes and bones.
  • In the second case, metastases to the sacrum and femur developed after surgery for a recurrent anaplastic oligoastrocytoma.
  • Our two cases reconfirm a rare but definite ability not only of glioblastoma but also of anaplastic oligodendroglioma, namely to metastasize to extraneural sites.
  • It is important to bear this in mind, particularly in cases when the history of primary brain tumor is unavailable.
  • In such instances, the correct diagnosis of the metastatic lesion may be extremely difficult if not impossible.
  • [MeSH-major] Astrocytoma / secondary. Brain Neoplasms / pathology. Femoral Neoplasms / secondary. Neoplasm Recurrence, Local. Oligodendroglia / pathology. Oligodendroglioma / secondary. Sacrum / pathology. Spinal Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19410385.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


31. Tsutsumi S, Abe Y, Yasumoto Y, Ito M: Anaplastic pleomorphic xanthoastrocytoma with a component of anaplastic astrocytoma presenting as skull base tumor followed by downward extracranial extension. Case report. Neurol Med Chir (Tokyo); 2010;50(12):1108-12
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic pleomorphic xanthoastrocytoma with a component of anaplastic astrocytoma presenting as skull base tumor followed by downward extracranial extension. Case report.
  • Histological examination revealed cellular pleomorphism with mitotic activity, focal necrosis, but lacking endothelial proliferation, consistent with anaplastic pleomorphic xanthoastrocytoma (PXA) with component of anaplastic astrocytoma.
  • PXA with anaplastic appearance may have a component of anaplastic astrocytoma with more aggressive behavior.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Skull Base Neoplasms / pathology

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • Genetic Alliance. consumer health - Pleomorphic xanthoastrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21206189.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


32. Guan Y, Mizoguchi M, Yoshimoto K, Hata N, Shono T, Suzuki SO, Araki Y, Kuga D, Nakamizo A, Amano T, Ma X, Hayashi K, Sasaki T: MiRNA-196 is upregulated in glioblastoma but not in anaplastic astrocytoma and has prognostic significance. Clin Cancer Res; 2010 Aug 15;16(16):4289-97
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MiRNA-196 is upregulated in glioblastoma but not in anaplastic astrocytoma and has prognostic significance.
  • EXPERIMENTAL DESIGN: In this study, we examined the expression levels of 365 mature human miRNAs in 12 malignant gliomas, including 8 glioblastomas and 4 anaplastic astrocytomas, using TaqMan real-time quantitative PCR arrays.
  • RESULTS: Expression profiles in glioblastomas and anaplastic astrocytomas suggested that 16 miRNAs were candidate markers associated with the malignant progression of gliomas.
  • Both miRNAs showed increased expression levels in glioblastomas relative to both anaplastic astrocytomas and normal brains in the validation study.
  • [MeSH-major] Astrocytoma / genetics. Biomarkers, Tumor / genetics. Brain Neoplasms / genetics. Glioblastoma / genetics. MicroRNAs / genetics

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20601442.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MIRN196 microRNA, human; 0 / MicroRNAs
  •  go-up   go-down


33. Cheong JH, Kim CH, Kim JM, Oh YH: Transformation of intracranial anaplastic astrocytoma associated with neurofibromatosis type I into gliosarcoma: case report. Clin Neurol Neurosurg; 2010 Oct;112(8):701-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transformation of intracranial anaplastic astrocytoma associated with neurofibromatosis type I into gliosarcoma: case report.
  • Gliosarcoma is an uncommon malignant brain tumor composed of distinct sarcomatous and malignant glial cell elements.
  • We report a rare case with gliosarcomatous recurrence of anaplastic astrocytoma with neurofibromatosis type 1 (NF-1) followed by chemoradiation therapy.
  • Histopathology of the tumor showed findings corresponding with anaplastic astrocytoma.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Gliosarcoma / pathology. Neoplasm Recurrence, Local / pathology. Neurofibromatosis 1 / pathology

  • Genetic Alliance. consumer health - Gliosarcoma.
  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • Genetic Alliance. consumer health - Neurofibromatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20466481.001).
  • [ISSN] 1872-6968
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


34. Muthukrishnan A, Bajoghli M, Mountz JM: Delayed development of radiation vasculopathy of the brain stem confirmed by F-18 FDG PET in a case of anaplastic astrocytoma. Clin Nucl Med; 2007 Jul;32(7):527-31
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Delayed development of radiation vasculopathy of the brain stem confirmed by F-18 FDG PET in a case of anaplastic astrocytoma.
  • We present the imaging findings of a 38-year-old female patient who underwent resection and radiation therapy for an anaplastic astrocytoma in her left temporal lobe 12 years ago.
  • Magnetic resonance imaging (MRI) of the brain showed a new mass lesion in the left pontine region of the brain stem.
  • Therefore, an F-18 FDG brain PET scan was performed, which demonstrated no metabolic activity in the pontine lesion leading to the less common diagnosis of long-term postradiation vasculopathy.
  • This case illustrates the importance of considering the rare diagnosis of radiation-induced vasculopathy in the differential diagnosis when symptoms of recurrent brain tumor occur.
  • [MeSH-major] Brain Stem / radionuclide imaging. Cerebrovascular Disorders / etiology. Cerebrovascular Disorders / radionuclide imaging. Fluorodeoxyglucose F18. Radiation Injuries / etiology. Radiation Injuries / radionuclide imaging. Radiotherapy / adverse effects
  • [MeSH-minor] Adult. Astrocytoma / radionuclide imaging. Astrocytoma / radiotherapy. Female. Humans. Positron-Emission Tomography / methods. Radiopharmaceuticals. Time Factors

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17581336.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


35. Baehring J, Hui P, Piepmeier J, Bannykh SI: Anaplastic oligoastrocytoma in Turcot syndrome. J Neurooncol; 2009 Nov;95(2):293-298
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic oligoastrocytoma in Turcot syndrome.
  • Turcot syndrome (TS), a rare variant of hereditary non-polyposis colorectal cancer (HNPCC), is characterized by familial clustering of cancer of the large bowel, extracolonic body sites and brain.
  • We report a 72 year old woman with anaplastic oligoastrocytoma in the setting of TS.
  • Careful analysis of tumor DNA is required to exclude the chance occurrence of a brain tumor in HNPCC kindreds and increase our understanding of the pathogenesis of the disease.
  • [MeSH-major] Astrocytoma / complications. Colorectal Neoplasms, Hereditary Nonpolyposis / complications

  • Genetic Alliance. consumer health - Anaplastic Oligoastrocytoma.
  • Genetic Alliance. consumer health - Oligoastrocytoma.
  • Genetic Alliance. consumer health - Turcot syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19495563.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / G-T mismatch-binding protein; 0 / MLH1 protein, human; 0 / Nuclear Proteins; EC 3.6.1.- / Adenosine Triphosphatases; EC 3.6.1.- / PMS2 protein, human; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / Mismatch Repair Endonuclease PMS2; EC 3.6.1.3 / MutL Protein Homolog 1; EC 3.6.1.3 / MutS Homolog 2 Protein; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


36. Pipas JM, Meyer LP, Rhodes CH, Cromwell LD, McDonnell CE, Kingman LS, Rigas JR, Fadul CE: A Phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma. J Neurooncol; 2005 Feb;71(3):301-5
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma.
  • PURPOSE: Therapy for high-grade gliomas remains unsatisfactory.
  • We conducted a Phase II trial of these agents in combination with filgrastim (G-CSF) in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma.
  • Hematologic toxicity was common with 25 /% of patients experiencing grade III or IV leukopenia despite G-CSF support.
  • CONCLUSION: Paclitaxel and topotecan with G-CSF support exhibits modest activity in adults with recurrent or refractory glioblastoma and anaplastic astrocytoma.
  • The significant hematotoxicity encountered, however, cannot justify further investigation of this combination in patients with high grade brain tumors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy. Neoplasm Recurrence, Local / drug therapy

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. Topotecan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15735921.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 7M7YKX2N15 / Topotecan; P88XT4IS4D / Paclitaxel; PVI5M0M1GW / Filgrastim
  •  go-up   go-down


37. See SJ, Ty A, Wong MC: Salvage chemotherapy in progressive high-grade astrocytoma. Ann Acad Med Singapore; 2007 May;36(5):343-6
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage chemotherapy in progressive high-grade astrocytoma.
  • INTRODUCTION: Despite aggressive multidisciplinary interventions, patients with high-grade astrocytomas experience tumour progression or recurrence.
  • MATERIALS AND METHODS: A retrospective review of relevant clinical and radiographic information of patients who received at least one cycle of salvage chemotherapy for progressive high-grade astrocytoma at the National Cancer Center, Singapore, from March 2004 to September 2006, was conducted.
  • Patients underwent regular assessment with clinical examination and magnetic resonance brain imaging to gauge response to salvage chemotherapy.
  • RESULTS: Twenty-four patients (13 glioblastomas, 11 anaplastic astrocytomas) had received chemotherapy as salvage treatment following progression of their high-grade astrocytoma.
  • For patients with anaplastic astrocytoma, the 12-month survival rate was 73%.
  • CONCLUSION: Durable disease control and prolonged survival were seen in a significant portion of selected patients with progressive high-grade astrocytoma who received salvage chemotherapy.
  • [MeSH-major] Astrocytoma / drug therapy. Glioblastoma / drug therapy. Salvage Therapy / methods
  • [MeSH-minor] Adult. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Female. Humans. Male. Middle Aged. Retrospective Studies. Singapore. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17549281.001).
  • [ISSN] 0304-4602
  • [Journal-full-title] Annals of the Academy of Medicine, Singapore
  • [ISO-abbreviation] Ann. Acad. Med. Singap.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  • [Chemical-registry-number] 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


38. Sadones J, Michotte A, Veld P, Chaskis C, Sciot R, Menten J, Joossens EJ, Strauven T, D'Hondt LA, Sartenaer D, Califice SF, Bierau K, Svensson C, De Grève J, Neyns B: MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma. Eur J Cancer; 2009 Jan;45(1):146-53
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma.
  • AIMS: To investigate the correlation between O(6)-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and benefit from temozolomide in patients with recurrent high-grade glioma.
  • RESULTS: A subgroup of 38 patients who were chemotherapy-naive at recurrence was analysed (22 glioblastoma, 12 anaplastic astrocytoma [AA] and 4 anaplastic oligoastrocytoma [AOA]); none had 1p/19q loss.
  • By Cox multivariate analysis, tumour grade and MGMT promoter methylation correlated with time to progression (p<0.05); MGMT promoter methylation correlated with superior overall survival in AA/AOA but not in glioblastoma.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. O(6)-Methylguanine-DNA Methyltransferase / genetics. Promoter Regions, Genetic

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18945611.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


39. Keles GE, Chang EF, Lamborn KR, Tihan T, Chang CJ, Chang SM, Berger MS: Volumetric extent of resection and residual contrast enhancement on initial surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. J Neurosurg; 2006 Jul;105(1):34-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Volumetric extent of resection and residual contrast enhancement on initial surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma.
  • OBJECT: To investigate the prognostic significance of the volumetrically assessed extent of resection on time to tumor progression (TTP), overall survival (OS), and tumor recurrence patterns, the authors retrospectively analyzed preoperative and postoperative tumor volumes in 102 adult patients from the time of the initial resection of a hemispheric anaplastic astrocytoma (AA).
  • In contrast to low-grade gliomas, there was no statistically significant relationship between the extent of resection and histological characteristics at the time of recurrence, that is, tumor Grade III compared with Grade IV.
  • [MeSH-major] Astrocytoma / pathology. Astrocytoma / surgery. Brain Neoplasms / pathology. Brain Neoplasms / surgery. Neoplasm Recurrence, Local / pathology

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16871879.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


40. Tsuji K, Nakasu S, Tsuji A, Fukami T, Nozaki K: [Postoperative regression of desmoplastic infantile astrocytoma]. No Shinkei Geka; 2008 Nov;36(11):1035-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Postoperative regression of desmoplastic infantile astrocytoma].
  • Desmoplastic infantile astrocytoma/ganglioglioma (DIA/DIG) is a rare tumor that is usually located superficially with a large cystic component.
  • In the central portion of the tumor, anaplastic features, such as necrosis, mitosis, and high nucleus-cytoplasmic ratio, were noticed.
  • Diagnosis was DIA.
  • [MeSH-major] Astrocytoma / pathology. Astrocytoma / surgery. Brain Neoplasms / pathology. Brain Neoplasms / surgery

  • Genetic Alliance. consumer health - Desmoplastic Infantile Astrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19048924.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


41. Fu YJ, Miyahara H, Uzuka T, Natsumeda M, Okamoto K, Hirose T, Fujii Y, Takahashi H: Intraventricular pleomorphic xanthoastrocytoma with anaplastic features. Neuropathology; 2010 Aug;30(4):443-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraventricular pleomorphic xanthoastrocytoma with anaplastic features.
  • However, considering the overall histopathological picture, a final diagnosis of PXA with anaplastic features was made.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Glioblastoma / pathology. Humans. Magnetic Resonance Imaging. Male. Middle Aged

  • Genetic Alliance. consumer health - Pleomorphic xanthoastrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20051018.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


42. Chang CL: Genome-wide oligonucleotide microarray analysis of gene-expression profiles of Taiwanese patients with anaplastic astrocytoma and glioblastoma multiforme. J Biomol Screen; 2008 Oct;13(9):912-21
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genome-wide oligonucleotide microarray analysis of gene-expression profiles of Taiwanese patients with anaplastic astrocytoma and glioblastoma multiforme.
  • The gene-expression profiles of approximately 20,000 genes from 4 anaplastic astrocytomas (AAs), 7 glioblastoma multiformes (GBMs), and 1 nontumor brain (NB) were analyzed by in situ-synthesized 60-mer oligonucleotide microarray.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Genome, Human. Glioblastoma / metabolism

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18812569.001).
  • [ISSN] 1087-0571
  • [Journal-full-title] Journal of biomolecular screening
  • [ISO-abbreviation] J Biomol Screen
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Oligonucleotides
  •  go-up   go-down


43. Williams G, Fahey FH, Treves ST, Kocak M, Pollack IF, Boyett JM, Kun LE, Poussaint TY: Exploratory evaluation of two-dimensional and three-dimensional methods of FDG PET quantification in pediatric anaplastic astrocytoma: a report from the Pediatric Brain Tumor Consortium (PBTC). Eur J Nucl Med Mol Imaging; 2008 Sep;35(9):1651-8
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exploratory evaluation of two-dimensional and three-dimensional methods of FDG PET quantification in pediatric anaplastic astrocytoma: a report from the Pediatric Brain Tumor Consortium (PBTC).
  • PURPOSE: The rationale of this study was to investigate the feasibility of three-dimensional (3D) methods to analyze (18)F-fluoro-deoxy-glucose (FDG) uptake in children with anaplastic astrocytoma (AA) in a multi-institutional trial, to compare 3D and two-dimensional (2D) methods and explore data associations with progression-free survival (PFS).
  • These methods yield an estimate of metabolically active tumor burden and may add prognostic information after tumor grade is determined.
  • [MeSH-major] Astrocytoma / diagnostic imaging. Brain Neoplasms. Fluorodeoxyglucose F18. Imaging, Three-Dimensional / methods. Organizations. Positron-Emission Tomography / methods
  • [MeSH-minor] Adolescent. Brain / metabolism. Brain / pathology. Child. Child, Preschool. Clinical Trials, Phase I as Topic. Female. Humans. Magnetic Resonance Imaging. Male. Neoplasm Staging. Phantoms, Imaging. Prognosis. Recurrence. Survival Rate

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 1987 Aug;164(2):521-6 [3496626.001]
  • [Cites] AJNR Am J Neuroradiol. 2007 Apr;28(4):603-7 [17416804.001]
  • [Cites] Mol Imaging Biol. 2006 May-Jun;8(3):141-50 [16534552.001]
  • [Cites] Neurology. 1982 Dec;32(12 ):1323-9 [6983044.001]
  • [Cites] Neurosurgery. 1996 Sep;39(3):470-6; discussion 476-7 [8875476.001]
  • [Cites] J Clin Oncol. 2006 Jul 10;24(20):3234-44 [16829647.001]
  • [Cites] Radiology. 1995 Apr;195(1):47-52 [7892494.001]
  • [Cites] J Clin Oncol. 2005 May 1;23 (13):3030-7 [15860860.001]
  • [Cites] Br J Radiol. 2006 Jan;79(937):32-6 [16421402.001]
  • [Cites] Clin Positron Imaging. 2000 Jul;3(4):152 [11150755.001]
  • [Cites] J Neurooncol. 2000 Sep;49(2):157-63 [11206011.001]
  • [Cites] J Comput Assist Tomogr. 1997 Jul-Aug;21(4):554-66 [9216759.001]
  • [Cites] Neuroimaging Clin N Am. 2002 Nov;12 (4):615-26 [12687915.001]
  • [Cites] Neuro Oncol. 2007 Apr;9(2):145-60 [17293590.001]
  • [Cites] J Neurooncol. 2003 Sep;64(3):227-37 [14558598.001]
  • [Cites] J Neurosurg. 1985 Jun;62(6):816-22 [2987440.001]
  • (PMID = 18425516.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / UM1 CA081457; United States / PHS HHS / / U01 A 81457
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


44. Zhao YC, Li NY, Zhou XJ, Zhou HB, Ma HH, Zhang RS: [Clinicopathologic study of pilocytic astrocytoma]. Zhonghua Bing Li Xue Za Zhi; 2008 Sep;37(9):609-14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic study of pilocytic astrocytoma].
  • OBJECTIVE: To study clinicopathologic features, treatment and prognosis of pilocytic astrocytoma (PA).
  • One case had anaplastic features.
  • All cases showed diffuse positive staining for GFAP and low expression for Ki-67, except 1 anaplastic tumor with 10% Ki-67 indices.
  • CONCLUSIONS: PA is a benign, WHO grade I tumor with favorable prognosis, and does not require radiotherapy after total resection.
  • The tumor can be mistaken as higher-grade astrocytoma when involving the subarachnoid space, and with cytological atypia, leading to unnecessary radiotherapy after surgery.
  • The outcome for patients with brainstem tumor or anaplastic PA is poor.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Glial Fibrillary Acidic Protein / genetics. Recurrence

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19094585.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein
  •  go-up   go-down


45. Arslantas A, Artan S, Oner U, Müslümanoglu MH, Ozdemir M, Durmaz R, Arslantas D, Vural M, Cosan E, Atasoy MA: Genomic alterations in low-grade, anaplastic astrocytomas and glioblastomas. Pathol Oncol Res; 2007;13(1):39-46
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic alterations in low-grade, anaplastic astrocytomas and glioblastomas.
  • To extend our understanding of potential stepwise genetic alterations that may underlie tumor progression from low-grade astrocytomas to glioblastomas, histopathologic and comparative genomic hybridization analyses were performed on tumor specimens from 68 primary lesions, including 40 glioblastomas, 10 anaplastic and 18 low-grade astrocytomas.
  • The number of aberrations per case increased towards the higher grade tumors (grade II: 1.66+/-1.49; grade III: 2.80+/-1.68; grade IV: 3.02+/-1.07; F=6.955, p=0.002).
  • A gain of 7/7q was common and the most frequently seen aberration in low-grade astrocytomas, whereas loss of 10q was the most frequently seen anomaly in anaplastic astrocytomas and glioblastomas.
  • Chromosome 10/10q deletion and combination of 1p, 19q and 17p deletions were specific to high-grade astrocytic tumors.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Chromosome Aberrations. Chromosome Deletion. Glioblastoma / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17387387.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


46. Passone E, Pizzolitto S, D'Agostini S, Skrap M, Gardiman MP, Nocerino A, Scarzello G, Perilongo G: Non-anaplastic pleomorphic xanthoastrocytoma with neuroradiological evidences of leptomeningeal dissemination. Childs Nerv Syst; 2006 Jun;22(6):614-8
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-anaplastic pleomorphic xanthoastrocytoma with neuroradiological evidences of leptomeningeal dissemination.
  • CASE REPORT: A case of a non-anaplastic pleomorphic xanthoastrocytoma (PXA) presenting with leptomeningeal dissemination (LMD) affecting a 9-year-old girl is presented.
  • CONCLUSION: To our knowledge, this is the first case of a non-anaplastic PXA presenting with disseminated disease.
  • [MeSH-major] Astrocytoma / complications. Brain Neoplasms / complications. Meningeal Neoplasms / complications. Neoplasm Recurrence, Local / etiology

  • Genetic Alliance. consumer health - Pleomorphic xanthoastrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1999 May 1;85(9):2033-45 [10223246.001]
  • [Cites] Neuropathol Appl Neurobiol. 1987 Nov-Dec;13(6):481-7 [3447073.001]
  • [Cites] Childs Nerv Syst. 2004 Feb;20(2):119-22 [14669022.001]
  • [Cites] J Neurooncol. 2001 Mar;52(1):63-72 [11451204.001]
  • [Cites] Histopathology. 1998 Apr;32(4):375-8 [9602336.001]
  • [Cites] Ann Neurol. 1985 Aug;18(2):217-21 [4037762.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):269-74 [8293186.001]
  • [Cites] Arch Pathol Lab Med. 1998 Dec;122(12):1082-6 [9870856.001]
  • [Cites] Childs Nerv Syst. 2003 Apr;19(4):197-203 [12682758.001]
  • (PMID = 16369851.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Ki-67 Antigen
  •  go-up   go-down


47. Momota H, Narita Y, Miyakita Y, Hosono A, Makimoto A, Shibui S: Acute lymphoblastic leukemia after temozolomide treatment for anaplastic astrocytoma in a child with a germline TP53 mutation. Pediatr Blood Cancer; 2010 Sep;55(3):577-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemia after temozolomide treatment for anaplastic astrocytoma in a child with a germline TP53 mutation.
  • We present a case of a 12-year-old female with a germline TP53 mutation who presented with anaplastic astrocytoma and subsequent acute lymphoblastic leukemia (ALL) 13 months after starting treatment with temozolomide (TMZ).
  • [MeSH-major] Antineoplastic Agents, Alkylating / adverse effects. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Frontal Lobe. Genes, p53 / genetics. Germ-Line Mutation. Neoplasms, Second Primary / chemically induced. Precursor Cell Lymphoblastic Leukemia-Lymphoma / chemically induced

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Wiley-Liss, Inc.
  • [ErratumIn] Pediatr Blood Cancer. 2011 Mar;56(3):509. Nariata, Yoshitaka [corrected to Narita, Yoshitaka]
  • (PMID = 20658636.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


48. Nishikawa R, Shibui S, Maruno M, Sugiyama K, Sato S, Fujimaki T, Takahashi H, Wakabayashi T, Takahashi J, Kochi M, Nakamura H, Sawamura Y, Ikeda J, Hori T, Aoki T, Matsutani M: [Efficacy and safety of monotherapy with temozolomide in patients with anaplastic astrocytoma at first relapse--a phase II clinical study]. Gan To Kagaku Ryoho; 2006 Sep;33(9):1279-85
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy and safety of monotherapy with temozolomide in patients with anaplastic astrocytoma at first relapse--a phase II clinical study].
  • The efficacy and safety of temozolomide were evaluated in 32 patients with anaplastic astrocytoma at first relapse.
  • The main laboratory test abnormalities (total incidence and incidence of grade 3/4 change) were lymphocytopenia (50%, 25%), neutropenia (47%, 6%), leukopenia (38%, 3%), thrombocytopenia (31%, 9%), and increased GPT (25%, 3%).
  • Temozolomide was shown to have good efficacy and tolerability in patients with anaplastic astrocytoma at first relapse.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16969025.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Clinical Trial, Phase II; English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


49. Chamberlain MC, Johnston S: Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma. Cancer; 2009 Apr 15;115(8):1734-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma.
  • BACKGROUND: A retrospective evaluation of single agent bevacizumab was carried out in adults with recurrent alkylator-refractory 1p19q codeleted anaplastic oligodendrogliomas (AO) with an objective of determining progression-free survival (PFS).
  • Bevacizumab-related toxicity included fatigue (14 patients; 4 grade 3), leukopenia (9; 1 grade 3), anemia (5; 0 grade 3), hypertension (5; 1 grade 3), deep vein thrombosis (4; 1 grade 3), and wound dehiscence (2; 1 grade 3).
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Brain Neoplasms / drug therapy. Oligodendroglioma / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma / drug therapy. Bevacizumab. Chromosomes, Human, Pair 1. Disease-Free Survival. Drug Resistance, Neoplasm. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19197992.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents, Alkylating; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


50. Neyns B, Chaskis C, Joosens E, Menten J, D'Hondt L, Branle F, Sadones J, Michotte A: A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma. Cancer Invest; 2008 Apr-May;26(3):269-77
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma.
  • This multicenter cohort study enrolled 19 patients (15 anaplastic astrocytoma, 4 anaplastic oligoastrocytoma) who received temozolomide (100 mg/m2/day for 21 consecutive days every 28-day cycle) at first recurrence, either until disease progression or 12 cycles.
  • Grade 3 and 4 lymphopenia occurred in 53% and 47% of patients, respectively.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy


51. Hyder DJ, Sung L, Pollack IF, Gilles FH, Yates AJ, Davis RL, Boyett JM, Finlay JL: Anaplastic mixed gliomas and anaplastic oligodendroglioma in children: results from the CCG 945 experience. J Neurooncol; 2007 May;83(1):1-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic mixed gliomas and anaplastic oligodendroglioma in children: results from the CCG 945 experience.
  • PURPOSE: To review interpathologist diagnosis variability and survival of children treated for either anaplastic mixed glioma (AMG) or anaplastic oligodendroglioma (AO) with surgery, irradiation and chemotherapy.
  • PATIENTS AND METHODS: Two hundred and fifty patients with an institutional diagnosis of malignant glioma were enrolled on Children's Cancer Group CCG-945 between 1985 and 1991, and administered vincristine during involved field radiotherapy, then six cycles of prednisone, lomustine and, vincristine; or two cycles of "eight-drugs-in-one-day" (8-in-1) chemotherapy then involved-field radiotherapy followed by six cycles of 8-in-1 chemotherapy.
  • However, central review established that only nine of 26 children had AMG: either mixed oligoastrocytoma (MOA) or anaplastic mixed oligoastrocytoma (AOA) and only one had AO.
  • CONCLUSION: Diagnosis of these tumors is challenging, with only 35% of institutional diagnoses confirmed for AMG and 25% for AO, and survival among children with these tumors is poor, despite intensive therapy.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Central Nervous System Neoplasms / therapy. Glioma / diagnosis. Glioma / therapy. Oligodendroglioma / diagnosis. Oligodendroglioma / therapy
  • [MeSH-minor] Adolescent. Astrocytoma / diagnosis. Astrocytoma / therapy. Brain Neoplasms / diagnosis. Brain Neoplasms / therapy. Child. Child, Preschool. Cohort Studies. Drug Therapy. Female. Humans. Infant. Male. Neurosurgical Procedures. Radiotherapy. Spinal Cord Neoplasms / diagnosis. Spinal Cord Neoplasms / therapy. Survival Analysis

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17252186.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] Netherlands
  •  go-up   go-down


52. Rao RD, Krishnan S, Fitch TR, Schomberg PJ, Dinapoli RP, Nordstrom K, Scheithauer B, O'Fallon JR, Maurer MJ, Buckner JC: Phase II trial of carmustine, cisplatin, and oral etoposide chemotherapy before radiotherapy for grade 3 astrocytoma (anaplastic astrocytoma): results of North Central Cancer Treatment Group trial 98-72-51. Int J Radiat Oncol Biol Phys; 2005 Feb 1;61(2):380-6
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of carmustine, cisplatin, and oral etoposide chemotherapy before radiotherapy for grade 3 astrocytoma (anaplastic astrocytoma): results of North Central Cancer Treatment Group trial 98-72-51.
  • PURPOSE: To evaluate the efficacy of preradiotherapy (RT) chemotherapy with carmustine, cisplatin, and oral etoposide combined with RT in the treatment of newly diagnosed anaplastic astrocytoma.
  • Grade 3-4 toxicities were observed in 14 patients (48%).
  • The primary study endpoint was the 23-month (700-day) survival, the median survival of patients with anaplastic astrocytoma in a previous North Central Cancer Treatment Group trial.
  • CONCLUSION: Our results have demonstrated that pre-RT chemotherapy with this regimen is insufficiently active in patients with anaplastic astrocytoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy. Astrocytoma / radiotherapy. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy


53. Schreuder T, Te Lintelo M, Kubat B, Koehler P: Anaplastic oligo-astrocytoma occurring after resection of a cerebral cavernous malformation; malignant transformation? Case report and review on etiology. J Neurol; 2010 Mar;257(3):349-53
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic oligo-astrocytoma occurring after resection of a cerebral cavernous malformation; malignant transformation? Case report and review on etiology.
  • Histological examination showed an anaplastic oligo-astrocytoma.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Hemangioma, Cavernous, Central Nervous System / complications. Hemangioma, Cavernous, Central Nervous System / surgery. Postoperative Complications / pathology
  • [MeSH-minor] Aged. Astrocytes / pathology. Brain / diagnostic imaging. Brain / pathology. Brain / physiopathology. Cell Transformation, Neoplastic. Disease Progression. Female. Humans. Magnetic Resonance Imaging. Neoplasm Invasiveness / pathology. Neoplasm Invasiveness / physiopathology. Neovascularization, Pathologic / etiology. Neovascularization, Pathologic / pathology. Neovascularization, Pathologic / physiopathology. Neurosurgical Procedures / adverse effects. Oligodendroglia / pathology. Tomography, X-Ray Computed


54. Yeh S, Fine HA, Smith JA: Corneal verticillata after dual anti-epidermal growth factor receptor and anti-vascular endothelial growth factor receptor 2 therapy (vandetanib) for anaplastic astrocytoma. Cornea; 2009 Jul;28(6):699-702
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Corneal verticillata after dual anti-epidermal growth factor receptor and anti-vascular endothelial growth factor receptor 2 therapy (vandetanib) for anaplastic astrocytoma.
  • PURPOSE: To describe a patient with a history of epithelial basement membrane dystrophy who developed symptomatic corneal verticillata after vandetanib therapy for anaplastic astrocytoma.
  • RESULTS: A 48-year-old female patient with a history of anaplastic astrocytoma status post resection, external beam radiation, and chemotherapy presented with glare symptoms, decreased contrast sensitivity, and increased lacrimation after approximately 12 months of therapy with the anti-epidermal growth factor receptor (EGFR) and anti-vascular endothelial growth factor receptor 2 protein tyrosine kinase inhibitor, vandetanib.
  • [MeSH-major] Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Corneal Diseases / chemically induced. Neoplasm Recurrence, Local / drug therapy. Piperidines / adverse effects. Quinazolines / adverse effects. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Vascular Endothelial Growth Factor Receptor-2 / antagonists & inhibitors

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • Hazardous Substances Data Bank. SODIUM CHLORIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19512898.001).
  • [ISSN] 1536-4798
  • [Journal-full-title] Cornea
  • [ISO-abbreviation] Cornea
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; 0 / Ointments; 0 / Piperidines; 0 / Quinazolines; 451W47IQ8X / Sodium Chloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2; EC 3.2.1.4 / Cellulase; EC 3.2.1.4 / carboxymethylcellulase
  •  go-up   go-down


55. Gururangan S, Frankel W, Broaddus R, Clendenning M, Senter L, McDonald M, Eastwood J, Reardon D, Vredenburgh J, Quinn J, Friedman HS: Multifocal anaplastic astrocytoma in a patient with hereditary colorectal cancer, transcobalamin II deficiency, agenesis of the corpus callosum, mental retardation, and inherited PMS2 mutation. Neuro Oncol; 2008 Feb;10(1):93-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multifocal anaplastic astrocytoma in a patient with hereditary colorectal cancer, transcobalamin II deficiency, agenesis of the corpus callosum, mental retardation, and inherited PMS2 mutation.
  • We describe the case of a patient with transcobalamin II deficiency, hypogammaglobulinemia, absent corpus callosum, and mental retardation who presented at an early age with colorectal cancer and multifocal anaplastic astrocytoma.
  • [MeSH-major] Abnormalities, Multiple / genetics. Adenosine Triphosphatases / genetics. Astrocytoma / genetics. Colorectal Neoplasms, Hereditary Nonpolyposis / genetics. DNA Repair Enzymes / genetics. DNA-Binding Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. Brain / pathology. Child. Child, Preschool. Colon / pathology. Corpus Callosum / pathology. DNA Mutational Analysis. Humans. Immunohistochemistry. Intellectual Disability / genetics. Intellectual Disability / pathology. Male. Mutation. Pedigree. Polymorphism, Single Nucleotide. Transcobalamins / deficiency


56. Buckner JC, O'Fallon JR, Dinapoli RP, Schomberg PJ, Farr G, Schaefer P, Giannini C, Scheithauer BW, Ballman KV: Prognosis in patients with anaplastic oligoastrocytoma is associated with histologic grade. J Neurooncol; 2007 Sep;84(3):279-86
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis in patients with anaplastic oligoastrocytoma is associated with histologic grade.
  • BACKGROUND: Anaplastic oligoastrocytomas (AOA) are relatively uncommon high-grade gliomas.
  • METHODS: Between 1980 and 1999, Mayo Clinic and the NCCTG conducted 10 trials of radiation therapy and chemotherapy in adults with newly-diagnosed high-grade gliomas.
  • We grouped patients by cell type and grade, compared survival distributions by the log-rank statistic, and performed multiple variable analyses.
  • RESULTS: Of 1368 patients, 68 (5%) had AOA, including 21 Grade 3 (OA3) and 47 grade 4 (OA4), 153 (11%) had anaplastic astrocytoma (AA), and 1147 (84%) had glioblastoma multiforme (GBM).
  • CONCLUSIONS: Patients with anaplastic oligoastrocytoma have distinct outcomes based upon grade (OA3 vs. OA4) and in comparison with pure astrocytoma (AA or GBM).
  • Future trials which include more than one histologic entity need to report results by cell type and grade and account for the varying prognoses in interpreting treatment outcomes.
  • [MeSH-major] Astrocytoma / mortality. Astrocytoma / pathology. Brain Neoplasms / mortality. Brain Neoplasms / pathology


57. Limentani SA, Asher A, Heafner M, Kim JW, Fraser R: A phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme. J Neurooncol; 2005 May;72(3):241-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme.
  • The purpose of this study was to evaluate combination chemotherapy with Gliadel wafer and carboplatin in patients with high-grade, malignant glioma.
  • Fourteen (88%) patients had glioblastoma multiforme and 2 (12%) had anaplastic astrocytoma.
  • No grade 3 or 4 toxicities were noted in this study.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma / drug therapy. Astrocytoma / radiotherapy. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Carboplatin / therapeutic use. Decanoic Acids / therapeutic use. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Polyesters / therapeutic use

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15937647.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Decanoic Acids; 0 / Drug Implants; 0 / Polyesters; 90409-78-2 / decanedioic acid-4,4'-(1,3-propanediylbis(oxy))bis(benzoic acid) copolymer; BG3F62OND5 / Carboplatin; U68WG3173Y / Carmustine
  •  go-up   go-down


58. Hildebrand J, Gorlia T, Kros JM, Afra D, Frenay M, Omuro A, Stupp R, Lacombe D, Allgeier A, van den Bent MJ, EORTC Brain Tumour Group investigators: Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882). Eur J Cancer; 2008 Jun;44(9):1210-6
Hazardous Substances Data Bank. Carmustine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882).
  • BACKGROUND: In a previous randomised EORTC study on adjuvant dibromodulcitol (DBD) and bichloroethylnitrosourea (BCNU) in adults with glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA), a clinically significant trend towards a longer overall survival (OS) and a progression-free survival (PFS) was observed in the subgroup of AA.
  • METHODS: Continuation of the previous phase III trial for newly diagnosed AA according to the local pathologist.
  • Central pathology review of grade 3 tumours remains crucial.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18248979.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA 11488
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] LJ2P1SIK8Y / Mitolactol; U68WG3173Y / Carmustine
  • [Investigator] Afra D; Maat B; Hildebrand J; de Wit O; Frenay F; Chatel M; Rivier I; Taphoorn M; Delattre JY; de Tribolet N; Stupp R; Punt J; Garfield J; Chinot O; van den Bent M; Lahrmann H; Cristo C; Mouchamps M; Haferkamp G; Bravo Marques J
  •  go-up   go-down


59. Sanders RP, Kocak M, Burger PC, Merchant TE, Gajjar A, Broniscer A: High-grade astrocytoma in very young children. Pediatr Blood Cancer; 2007 Dec;49(7):888-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-grade astrocytoma in very young children.
  • BACKGROUND: High-grade astrocytomas are rare in young children, but have been reported to have a better prognosis than similar tumors in older patients.
  • PROCEDURE: We retrospectively reviewed the clinical characteristics, survival, and long-term sequelae for patients younger than 3 years old with high-grade astrocytoma, treated at a single institution between 1984 and 2005.
  • Histology included anaplastic astrocytoma (n = 9), glioblastoma multiforme (n = 5), and malignant glioma (n = 2).
  • Age at diagnosis was a significant predictor of the hazard of death in a Cox model (HR 2.871, 95%CI 1.015-8.123).
  • All evaluable survivors (n = 9) had some neurocognitive impairment, with estimated overall cognitive ability ranging from significantly delayed to average; all survivors attending school (n = 5) performed below grade level on achievement testing.
  • CONCLUSIONS: Young children with high-grade astrocytoma have better long-term overall survival than older patients, but recurrence is common, and most children require irradiation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / therapy. Brain Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 Wiley-Liss, Inc
  • [CommentIn] Pediatr Blood Cancer. 2007 Dec;49(7):879-80 [17941062.001]
  • (PMID = 17554787.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 21765
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


60. Temel SG, Kahveci Z: Cyclooxygenase-2 expression in astrocytes and microglia in human oligodendroglioma and astrocytoma. J Mol Histol; 2009 Oct;40(5-6):369-77
Genetic Alliance. consumer health - Oligodendroglioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclooxygenase-2 expression in astrocytes and microglia in human oligodendroglioma and astrocytoma.
  • Cox-2 is cytokine-inducible in inflammatory cells and enhanced cox-2 expression has been attributed a key role in the development of edema and immunomodulation in pathologically altered brain tissues.
  • For this purpose we employed dual immunohistochemistry for cox-2 and GFAP (astrocyte) or LCA-MAC (microglia-macrophage) in archival formalin-fixed, paraffin embedded human tissue diagnosed as oligodendroglioma and/or astrocytoma.
  • The results showed that cox-2 immunoreactivity is up-regulated in the neurons according to the tumor grade.
  • Most of the cox-2 immunoreactive glia were GFAP-positive in anaplastic oligodendrogliomas and at lesser extend in glioblastomas.
  • [MeSH-major] Astrocytes / enzymology. Astrocytoma / enzymology. Cyclooxygenase 2 / metabolism. Microglia / enzymology. Oligodendroglioma / enzymology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20052522.001).
  • [ISSN] 1567-2387
  • [Journal-full-title] Journal of molecular histology
  • [ISO-abbreviation] J. Mol. Histol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


61. Rodriguez FJ, Scheithauer BW, Burger PC, Jenkins S, Giannini C: Anaplasia in pilocytic astrocytoma predicts aggressive behavior. Am J Surg Pathol; 2010 Feb;34(2):147-60
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplasia in pilocytic astrocytoma predicts aggressive behavior.
  • The clinical significance of anaplastic features, a rare event in pilocytic astrocytoma (PA), is not fully established.
  • We reviewed 34 PA with anaplastic features (Male = 21, Female = 13; median age 35 y, 5 to 75) among approximately 2200 PA cases (1.7%).
  • The tumors either had a PA precursor, coexistent (n = 14) (41%) or documented by previous biopsy (n = 10) (29%), or exhibited typical pilocytic features in an otherwise anaplastic astrocytoma (n = 10) (29%).
  • Histologically, the anaplastic component was classified as pilocytic like (41%), small cell (32%), epithelioid (15%), or fibrillary (12%).
  • Median MIB1 labeling index was 24.7% in the anaplastic component and 2.6% in the precursor, although overlapping values were present.
  • Median overall and progression-free survivals after diagnosis for the entire study group were 24 and 14 months, respectively.
  • In summary, PA with anaplastic features exhibits a spectrum of morphologies and is associated with decreased survival when compared with typical PA.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20061938.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 6.3.2.19 / MIB1 ligase, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


62. Chamberlain MC, Chowdhary SA, Glantz MJ: Anaplastic astrocytomas: biology and treatment. Expert Rev Neurother; 2008 Apr;8(4):575-86
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic astrocytomas: biology and treatment.
  • Anaplastic astrocytomas (AA), WHO grade III gliomas, comprise 10-15% of all glial neoplasms.
  • The most important predictor of response to therapy and survival in AA tumors is the presence or absence of the 1p19q co-deletion, a translocation that defines a subset of oligodendroglial tumors, and anaplastic oligodendrogliomas in particular.
  • [MeSH-major] Astrocytoma / diagnosis. Astrocytoma / therapy. Brain Neoplasms / diagnosis. Brain Neoplasms / therapy. Clinical Trials as Topic

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18416660.001).
  • [ISSN] 1744-8360
  • [Journal-full-title] Expert review of neurotherapeutics
  • [ISO-abbreviation] Expert Rev Neurother
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


63. Maciá Escalante S, Rodríguez Lescure A, Segura Ibáñez JM, Sáez Castán J, Guillén Ponce C, Carrato Mena A: Patient with resected anaplastic astrocytoma and an image suggestive of relapse. Clin Transl Oncol; 2006 Dec;8(12):912-4
Hazardous Substances Data Bank. Carmustine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patient with resected anaplastic astrocytoma and an image suggestive of relapse.
  • The main treatment of asctrocytomas is surgery, which serves a double purpose: diagnosis and treatment.
  • With respect to chemotherapy, there continues to be a controversy as to whether it has the capacity to overcome the blood-brain barrier.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Edema / radiography. Brain Neoplasms / diagnosis. Neoplasm Recurrence, Local / diagnosis

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17169765.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Decanoic Acids; 0 / Polyesters; 90409-78-2 / decanedioic acid-4,4'-(1,3-propanediylbis(oxy))bis(benzoic acid) copolymer; U68WG3173Y / Carmustine
  •  go-up   go-down


64. Rao SA, Santosh V, Somasundaram K: Genome-wide expression profiling identifies deregulated miRNAs in malignant astrocytoma. Mod Pathol; 2010 Oct;23(10):1404-17
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genome-wide expression profiling identifies deregulated miRNAs in malignant astrocytoma.
  • Malignant astrocytoma includes anaplastic astrocytoma (grade III) and glioblastoma (grade IV).
  • Among them, glioblastoma is the most common primary brain tumor with dismal responses to all therapeutic modalities.
  • We performed a large-scale, genome-wide microRNA (miRNA) (n=756) expression profiling of 26 glioblastoma, 13 anaplastic astrocytoma and 7 normal brain samples with an aim to find deregulated miRNA in malignant astrocytoma.
  • We identified several differentially regulated miRNAs between these groups, which could differentiate glioma grades and normal brain as recognized by PCA.
  • More importantly, we identified a most discriminatory 23-miRNA expression signature, by using PAM, which precisely distinguished glioblastoma from anaplastic astrocytoma with an accuracy of 95%.
  • Thus we have identified the miRNA expression signature for malignant astrocytoma, in particular glioblastoma, and showed the miRNA involvement and their importance in astrocytoma development.
  • [MeSH-major] Astrocytoma / genetics. Biomarkers, Tumor / genetics. Brain Neoplasms / genetics. MicroRNAs / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20711171.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MicroRNAs
  •  go-up   go-down


65. Chaichana KL, Kosztowski T, Niranjan A, Olivi A, Weingart JD, Laterra J, Brem H, Quiñones-Hinojosa A: Prognostic significance of contrast-enhancing anaplastic astrocytomas in adults. J Neurosurg; 2010 Aug;113(2):286-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of contrast-enhancing anaplastic astrocytomas in adults.
  • OBJECT: Patients harboring anaplastic astrocytomas (AAs) typically have a poor prognosis, with median survival times of approximately 3 years following resection.
  • [MeSH-major] Astrocytoma / mortality. Astrocytoma / pathology. Brain Neoplasms / mortality. Brain Neoplasms / pathology. Magnetic Resonance Imaging / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20302391.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


66. Somasundaram K, Reddy SP, Vinnakota K, Britto R, Subbarayan M, Nambiar S, Hebbar A, Samuel C, Shetty M, Sreepathi HK, Santosh V, Hegde AS, Hegde S, Kondaiah P, Rao MR: Upregulation of ASCL1 and inhibition of Notch signaling pathway characterize progressive astrocytoma. Oncogene; 2005 Oct 27;24(47):7073-83
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upregulation of ASCL1 and inhibition of Notch signaling pathway characterize progressive astrocytoma.
  • Astrocytoma is the most common type of brain cancer constituting more than half of all brain tumors.
  • With an aim to identify markers describing astrocytoma progression, we have carried out microarray analysis of astrocytoma samples of different grades using cDNA microarray containing 1152 cancer-specific genes.
  • Data analysis identified several differentially regulated genes between normal brain tissue and astrocytoma as well as between grades II/III astrocytoma and glioblastoma multiforme (GBM; grade IV).
  • As ASCL has been implicated in neuroendocrine, medullary thyroid and small-cell lung cancers, we chose to examine the role of ASCL1 in the astrocytoma development.
  • Our data revealed that ASCL1 is overexpressed in progressive astrocytoma as evidenced by increased levels of ASCL1 transcripts in 85.71% (6/7) of grade II diffuse astrocytoma (DA), 90% (9/10) of grade III anaplastic astrocytoma (AA) and 87.5% (7/8) of secondary GBMs, while the majority of primary de novo GBMs expressed similar to or less than normal brain levels (66.67%; 8/12).
  • ASCL1 upregulation in progressive astrocytoma is accompanied by inhibition of Notch signaling as seen by uninduced levels of HES1, a transcriptional target of Notch1, increased levels of HES6, a dominant-negative inhibitor of HES1-mediated repression of ASCL1, and increased levels of Notch ligand Delta1, which is capable of inhibiting Notch signaling by forming intracellular Notch ligand autonomous complexes.
  • Our results imply that inhibition of Notch signaling may be an important early event in the development of grade II DA and subsequent progression to grade III AA and secondary GBM.
  • [MeSH-major] Astrocytoma / genetics. DNA-Binding Proteins / metabolism. Gene Expression Regulation, Neoplastic. Glioblastoma / genetics. Membrane Proteins / metabolism. Signal Transduction. Transcription Factors / metabolism
  • [MeSH-minor] Basic Helix-Loop-Helix Transcription Factors. Brain / metabolism. Brain / pathology. Brain Neoplasms / genetics. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Disease Progression. Gene Expression Profiling. Helix-Loop-Helix Motifs. Humans. Oligonucleotide Array Sequence Analysis. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Receptors, Notch. Reverse Transcriptase Polymerase Chain Reaction. Up-Regulation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16103883.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ASCL1 protein, human; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / DNA-Binding Proteins; 0 / Membrane Proteins; 0 / RNA, Neoplasm; 0 / Receptors, Notch; 0 / Transcription Factors
  •  go-up   go-down


67. Vogelbaum MA, Berkey B, Peereboom D, Macdonald D, Giannini C, Suh JH, Jenkins R, Herman J, Brown P, Blumenthal DT, Biggs C, Schultz C, Mehta M: Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. Neuro Oncol; 2009 Apr;11(2):167-75
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131.
  • The primary objectives of this phase II study were to evaluate the use of preirradiation temozolomide followed by concurrent temozolomide and radiotherapy (RT) in patients with newly diagnosed anaplastic oligodendroglioma (AO) and mixed anaplastic oligoastrocytoma (MOA).
  • The worst nonhematological toxicity was grade 4 in three patients (8%).
  • There were no grade 4 nonhematological toxicities during the concurrent chemotherapy and RT.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Astrocytoma / therapy. Brain Neoplasms / therapy. Dacarbazine / analogs & derivatives. Neoplasm Recurrence, Local / therapy. Oligodendroglioma / therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Treat Rev. 1997 Jan;23(1):35-61 [9189180.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2013-21 [7931469.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] Oncogene. 1999 Jul 15;18(28):4144-52 [10435596.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9852-61 [17047046.001]
  • [Cites] Neuro Oncol. 2007 Jul;9(3):314-8 [17435180.001]
  • [Cites] J Neurosurg. 1996 Oct;85(4):602-7 [8814163.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):825-30 [11020580.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):839-45 [11309331.001]
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2449-55 [11331324.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4689-92 [11406538.001]
  • [Cites] Neurology. 2001 Jul 24;57(2):340-2 [11468326.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):552-60 [11905710.001]
  • [Cites] J Neurooncol. 2003 Feb;61(3):267-73 [12675321.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2525-8 [12829671.001]
  • [Cites] J Neurooncol. 2003 Sep;64(3):271-8 [14558604.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] J Neurosurg. 1985 Dec;63(6):881-9 [4056902.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Cancer Res. 1998 Oct 1;58(19):4363-7 [9766665.001]
  • (PMID = 18779504.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Tumor Suppressor Proteins; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  • [Other-IDs] NLM/ PMC2718988
  •  go-up   go-down


68. Radulović D: [Natural history of supratentorial low-grade astrocytoma: case report]. Srp Arh Celok Lek; 2006 Nov-Dec;134(11-12):537-40
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Natural history of supratentorial low-grade astrocytoma: case report].
  • Low-grade astrocytomas comprise a group of primary brain neoplasms with relatively low anaplastic potential, although through time they tend to behave more aggressively.
  • This report presents a natural history of a patient with low grade astrocytoma.
  • Initial computerized tomography and magnetic resonance of brain revealed oval, 4 cm in diameter, lesion in the left parietal region that was considered as low-grade glioma.
  • The described patient with low-grade astrocytoma lived without any oncological treatment eight years and four months from the time when diagnosis was made until intracranial herniation.
  • The natural history of disease in presented patient indicated that rational therapeutic strategy, for low-grade astrocytoma with epilepsy only, would be deferral of surgery until the time of manifestation of neurological or radiological deterioration.
  • [MeSH-major] Astrocytoma. Brain Neoplasms. Parietal Lobe

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17304770.001).
  • [ISSN] 0370-8179
  • [Journal-full-title] Srpski arhiv za celokupno lekarstvo
  • [ISO-abbreviation] Srp Arh Celok Lek
  • [Language] srp
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


69. Ellis JA, Waziri A, Balmaceda C, Canoll P, Bruce JN, Sisti MB: Rapid recurrence and malignant transformation of pilocytic astrocytoma in adult patients. J Neurooncol; 2009 Dec;95(3):377-382
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid recurrence and malignant transformation of pilocytic astrocytoma in adult patients.
  • Pilocytic astrocytoma is a slow-growing, circumscribed glioma that most frequently occurs within the pediatric population.
  • In general, surgical resection for pilocytic astrocytoma is thought to be curative with tumor recurrence or malignant transformation being relatively rare.
  • However, there have been very few studies specifically looking at the prognosis for adult patients diagnosed with pilocytic astrocytoma.
  • To evaluate the frequency of recurrence and malignant transformation of pilocytic astrocytoma in adults, we performed a retrospective analysis of all adult patients who underwent surgical resection for this tumor at our institution over a period of 10 years.
  • A high rate of malignant transformation was observed in the patients that underwent repeat surgery with 75% (3/4) progressing to anaplastic astrocytoma on pathological examination.
  • This study provides further evidence that the clinical course of a subset of adult patients with pilocytic astrocytoma will not be benign.
  • [MeSH-major] Astrocytoma / mortality. Astrocytoma / pathology. Brain Neoplasms / mortality. Brain Neoplasms / pathology. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19533024.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Söling A, Sackewitz M, Volkmar M, Schaarschmidt D, Jacob R, Holzhausen HJ, Rainov NG: Minichromosome maintenance protein 3 elicits a cancer-restricted immune response in patients with brain malignancies and is a strong independent predictor of survival in patients with anaplastic astrocytoma. Clin Cancer Res; 2005 Jan 1;11(1):249-58
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minichromosome maintenance protein 3 elicits a cancer-restricted immune response in patients with brain malignancies and is a strong independent predictor of survival in patients with anaplastic astrocytoma.
  • EXPERIMENTAL DESIGN: Tumor-associated antigens were identified by immunoscreening of a human glioma cDNA expression library with allogeneic sera from patients with diffuse astrocytoma (WHO grades 2-4).
  • In addition, 98 serum specimens from patients with primary and secondary brain malignancies and 30 serum specimens from healthy controls were examined by serologic immunoscreening for immunoreactivity with MCM3.
  • RESULTS: MCM3 is overexpressed in human astrocytic tumors and elicits a cancer-restricted humoral immune response in 9.3% (9 of 97) of patients with brain tumors (n = 95) and brain metastases (n = 2) but not in healthy controls.
  • Expression of MCM3 in diffuse astrocytoma is significantly associated with age (P < 0.001), histologic grade (P < 0.001), time to recurrence (P = 0.01), and expression of the proliferation marker Ki-67 (P < 0.001) but not with sex (P = 0.800).
  • Univariate and multivariate Cox regression analysis confirmed MCM3 expression as an independent predictor of poor outcome in astrocytoma patients (P < 0.001 for both).
  • [MeSH-major] Astrocytoma / immunology. Astrocytoma / mortality. Brain Neoplasms / immunology. Brain Neoplasms / mortality. DNA-Binding Proteins / physiology. Gene Expression Regulation, Neoplastic. Nuclear Proteins / physiology. Transcription Factors / physiology

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • Genetic Alliance. consumer health - Brain Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15671553.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / DNA, Complementary; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; 0 / MCM3 protein, human; 0 / Nuclear Proteins; 0 / Transcription Factors; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 3
  •  go-up   go-down


71. Matusan-Ilijas K, Behrem S, Jonjic N, Zarkovic K, Lucin K: Osteopontin expression correlates with angiogenesis and survival in malignant astrocytoma. Pathol Oncol Res; 2008 Sep;14(3):293-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteopontin expression correlates with angiogenesis and survival in malignant astrocytoma.
  • Seventy-six human astrocytomas including eight pilocytic astrocytomas (grade I), 10 diffuse astrocytomas (grade II), 8 anaplastic astrocytomas (grade III) and 50 glioblastomas (grade IV) were immunohistochemically stained for OPN protein.
  • In normal brain tissue some glial and neuronal cells showed weak cytoplasmic staining, while interstitium was negative.
  • Our results indicate the overexpression of OPN protein in astrocytoma cells and suggest the role of OPN in astrocytoma progression and angiogenesis.
  • [MeSH-major] Astrocytoma / blood supply. Astrocytoma / metabolism. Biomarkers, Tumor / metabolism. Brain Neoplasms / blood supply. Brain Neoplasms / metabolism. Neovascularization, Pathologic / metabolism. Osteopontin / metabolism
  • [MeSH-minor] Brain / blood supply. Brain / metabolism. Brain / pathology. Disease Progression. Humans. Kaplan-Meier Estimate. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18493866.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 106441-73-0 / Osteopontin
  •  go-up   go-down


72. Sathornsumetee S, Rich JN, Reardon DA: Diagnosis and treatment of high-grade astrocytoma. Neurol Clin; 2007 Nov;25(4):1111-39, x
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and treatment of high-grade astrocytoma.
  • High-grade astrocytomas include the most common adult central nervous system (CNS) tumor, glioblastoma multiforme, and anaplastic astrocytoma--a highly aggressive cancer with short median survival despite maximal multimodality therapy.
  • Diagnosis is by clinical and radiographic findings confirmed by histopathology.
  • Nearly all patients who have high-grade astrocytomas develop tumor recurrence or progression after this multimodality treatment.
  • This article discusses diagnosis and current treatment of high-grade astrocytomas.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Astrocytoma / pathology. Astrocytoma / therapy. Brain Neoplasms / pathology. Brain Neoplasms / therapy. Dacarbazine / analogs & derivatives
  • [MeSH-minor] Brachytherapy. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Magnetic Resonance Spectroscopy. Neoplasm Staging. Neurosurgical Procedures / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17964028.001).
  • [ISSN] 0733-8619
  • [Journal-full-title] Neurologic clinics
  • [ISO-abbreviation] Neurol Clin
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1 P20 CA096890; United States / NCI NIH HHS / CA / CA11898; United States / NINDS NIH HHS / NS / NS20023
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  • [Number-of-references] 142
  •  go-up   go-down


73. Inagawa H, Ishizawa K, Hirose T: Qualitative and quantitative analysis of cytologic assessment of astrocytoma, oligodendroglioma and oligoastrocytoma. Acta Cytol; 2007 Nov-Dec;51(6):900-6
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Qualitative and quantitative analysis of cytologic assessment of astrocytoma, oligodendroglioma and oligoastrocytoma.
  • OBJECTIVE: To evaluate the usefulness of intraoperative cytology for differential diagnoses of astrocytoma, oligodendroglioma and oligoastrocytoma.
  • STUDY DESIGN: Qualitative analysis of cytologic features of the 3 brain tumors was conducted using intraoperative touch or squash preparations that were stained with the Papanicolaou method, targeting the cellular density, cytoplasmic and nuclear profiles and blood vessel morphology.
  • In both tumors of a higher grade, anaplastic large nuclei and proliferating endothelial cells were noted.
  • CONCLUSION; Cytologic evaluation using touch or squash preparations is of great help for intraoperative differential diagnosis of astrocytoma, oligodendroglioma and oligoastrocytoma.
  • Cytologic as well as histologic assessment should be conducted at the intraoperative diagnosis of these tumors.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Cytodiagnosis / methods. Oligodendroglioma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Count. Cell Nucleus / pathology. Child. Child, Preschool. Cytoplasm / pathology. Diagnosis, Differential. Female. Humans. Image Processing, Computer-Assisted. Intraoperative Period. Male. Middle Aged


74. Uro-Coste E, Ssi-Yan-Kai G, Guilbeau-Frugier C, Boetto S, Bertozzi AI, Sevely A, Lolmede K, Delisle MB: Desmoplastic infantile astrocytoma with benign histological phenotype and multiple intracranial localizations at presentation. J Neurooncol; 2010 May;98(1):143-9
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Desmoplastic infantile astrocytoma with benign histological phenotype and multiple intracranial localizations at presentation.
  • Desmoplastic infantile astrocytoma (DIA) and desmoplastic infantile ganglioglioma (DIG) are rare intracranial tumors that mostly occur in the first 2 years of life and involve superficial cerebral cortex.
  • We report an original observation of a desmoplastic infantile astrocytoma in a 5-year-old boy with multiple localizations on initial presentation, including the unusual subtentorial region.
  • The surgical samples, corresponding exclusively to subtentorial lesions, were devoid of anaplastic features; the temporal lesion was untouched because of the interpeduncular extension.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology
  • [MeSH-minor] Brain / pathology. Brain / radiography. Child, Preschool. Humans. Magnetic Resonance Imaging / methods. Male. Tomography Scanners, X-Ray Computed

  • Genetic Alliance. consumer health - Desmoplastic Infantile Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20012157.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Quon H, Abdulkarim B: Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas. Cochrane Database Syst Rev; 2008;(2):CD007104
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas.
  • Outcomes analyzed include overall survival (OS), progression-free survival (PFS), and treatment toxicity greater than or equal to grade 3.
  • Based on the differences in patient selection with respect to the definition of AO (2 versus 3 high risk anaplastic features) and sequence of treatment (RT and chemotherapy), the results from the two RCTs were not able to be considered for meta-analysis.
  • [MeSH-major] Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Oligodendroglioma / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateIn] Cochrane Database Syst Rev. 2014;5:CD007104 [24833028.001]
  • (PMID = 18425979.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 11
  •  go-up   go-down


76. Wick W, Weller M: [Anaplastic glioma. Neuropathology, molecular diagnostics and current study concepts]. Nervenarzt; 2010 Aug;81(8):928-30, 932-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anaplastic glioma. Neuropathology, molecular diagnostics and current study concepts].
  • According to the current WHO classification anaplastic gliomas comprise pure astrocytomas and oligodendrogliomas and mixed tumors.
  • This review summarizes findings, discusses problems and defines new questions from the phase III trials on anaplastic gliomas.
  • Therefore, marker profiles should be included into the next WHO brain tumor classification.
  • The current standard of care for first-line treatment in anaplastic gliomas is radiotherapy or chemotherapy.
  • Inclusion in this trial is already based on the WHO grade and the 1p/19q status and not on the histopathological subtype.
  • Furthermore, anaplastic gliomas are an important group of brain tumors for developing future molecular targeted therapies and should therefore be in the main focus of academic and industrial drug development, which aims at improved efficacy and avoiding long-term side-effects.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Oligodendroglioma / pathology
  • [MeSH-minor] Antineoplastic Agents, Alkylating / therapeutic use. Brain / pathology. Chromosome Deletion. Clinical Trials as Topic. Clinical Trials, Phase III as Topic. Combined Modality Therapy. Cranial Irradiation. DNA Modification Methylases / genetics. DNA Mutational Analysis. DNA Repair Enzymes / genetics. Disease-Free Survival. Humans. Isocitrate Dehydrogenase / genetics. Promoter Regions, Genetic / genetics. Survival Rate. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet Oncol. 2009 May;10 (5):459-66 [19269895.001]
  • [Cites] J Neurol. 2009 May;256(5):734-41 [19240962.001]
  • [Cites] Science. 2009 Apr 10;324(5924):261-5 [19359588.001]
  • [Cites] Cancer Res. 2009 May 15;69(10 ):4502-9 [19366800.001]
  • [Cites] Eur J Cancer. 2008 Jun;44(9):1210-6 [18248979.001]
  • [Cites] J Neurooncol. 2009 May;92(3):401-15 [19357966.001]
  • [Cites] J Clin Oncol. 2010 Apr 20;28(12 ):2051-7 [20308655.001]
  • [Cites] Nat Rev Neurol. 2010 Jan;6(1):39-51 [19997073.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] N Engl J Med. 2000 Nov 9;343(19):1350-4 [11070098.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):392-401 [16648043.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3276-84 [12947063.001]
  • [Cites] Neuro Oncol. 2008 Dec;10 (6):1019-24 [18676355.001]
  • [Cites] J Clin Oncol. 2009 Dec 10;27(35):5881-6 [19901104.001]
  • [Cites] J Clin Oncol. 2010 Apr 10;28(11):1963-72 [20231676.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Oct;65(10):988-94 [17021403.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Neuro Oncol. 2009 Dec;11(6):737-46 [19224764.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9852-61 [17047046.001]
  • [Cites] J Clin Oncol. 2009 Oct 1;27(28):4733-40 [19720927.001]
  • [Cites] Cancer Cell. 2010 May 18;17(5):510-22 [20399149.001]
  • [Cites] Clin Cancer Res. 2008 Nov 1;14 (21):7068-73 [18981004.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3357-61 [17664483.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] Brain Pathol. 2002 Apr;12(2):257-9 [11958379.001]
  • [Cites] N Engl J Med. 2009 Feb 19;360(8):765-73 [19228619.001]
  • [Cites] J Clin Oncol. 2009 Dec 10;27(35):5874-80 [19901110.001]
  • [Cites] Acta Neuropathol. 2009 Oct;118(4):469-74 [19554337.001]
  • [Cites] J Clin Oncol. 2006 Mar 10;24(8):1281-8 [16525183.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • [Cites] J Neurosurg. 2008 Feb;108(2):330-5 [18240930.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):997-1003 [15758010.001]
  • [Cites] Clin Cancer Res. 2007 Dec 1;13(23):6933-7 [18056167.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] Neurology. 2006 Jan 24;66(2):239-42 [16434662.001]
  • (PMID = 20635074.001).
  • [ISSN] 1433-0407
  • [Journal-full-title] Der Nervenarzt
  • [ISO-abbreviation] Nervenarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Tumor Suppressor Proteins; EC 1.1.1.41 / Isocitrate Dehydrogenase; EC 1.1.1.42. / IDH1 protein, human; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


77. Momota H, Narita Y, Matsushita Y, Miyakita Y, Shibui S: p53 abnormality and tumor invasion in patients with malignant astrocytoma. Brain Tumor Pathol; 2010 Oct;27(2):95-101
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p53 abnormality and tumor invasion in patients with malignant astrocytoma.
  • To elucidate the relationship between p53 abnormality and invasiveness of the tumors, we studied mutation and protein expression of p53 in 48 consecutive patients with malignant astrocytoma (14 anaplastic astrocytomas and 34 glioblastoma multiformes).
  • [MeSH-major] Astrocytoma / genetics. Astrocytoma / pathology. Brain Neoplasms / genetics. Brain Neoplasms / pathology. Genes, p53 / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21046311.001).
  • [ISSN] 1861-387X
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Glial Fibrillary Acidic Protein; 0 / Tumor Suppressor Protein p53; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


78. MacDonald TJ, Pollack IF, Okada H, Bhattacharya S, Lyons-Weiler J: Progression-associated genes in astrocytoma identified by novel microarray gene expression data reanalysis. Methods Mol Biol; 2007;377:203-22
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progression-associated genes in astrocytoma identified by novel microarray gene expression data reanalysis.
  • Astrocytoma is graded as pilocytic (WHO grade I), diffuse (WHO grade II), anaplastic (WHO grade III), and glioblastoma multiforme (WHO grade IV).
  • The progression from low- to high-grade astrocytoma is associated with distinct molecular changes that vary with patient age, yet the prognosis of high-grade tumors in children and adults is equally dismal.
  • Whether specific gene expression changes are consistently associated with all high-grade astrocytomas, independent of patient age, is not known.
  • We identified nine genes consistently dysregulated in high-grade tumors, using four novel tests for identifying differentially expressed genes.
  • Four genes encoding ribosomal proteins (RPS2, RPS8, RPS18, RPL37A) were upregulated, and five genes (APOD, SORL1, SPOCK2, PRSS11, ID3) were downregulated in high-grade by all tests.
  • Expression results were validated using a third astrocytoma dataset.
  • This suggests that dysregulation of APOD may be critical for malignant astrocytoma formation, and thus a possible novel universal target for therapeutic intervention.
  • Further investigation is needed to evaluate the role of APOD, as well as the other genes identified, in malignant astrocytoma development.
  • [MeSH-major] Astrocytoma / genetics. Biomarkers, Tumor / genetics. Brain Neoplasms / genetics. Gene Expression. Oligonucleotide Array Sequence Analysis / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17634619.001).
  • [ISSN] 1064-3745
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 49
  •  go-up   go-down


79. Nagy M, Schulz-Ertner D, Bischof M, Welzel T, Hof H, Debus J, Combs SE: Long-term outcome of postoperative irradiation in patients with newly diagnosed WHO grade III anaplastic gliomas. Tumori; 2009 May-Jun;95(3):317-24
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of postoperative irradiation in patients with newly diagnosed WHO grade III anaplastic gliomas.
  • PURPOSE: Patients with anaplastic gliomas have a more favorable overall survival than patients with glioblastomas.
  • In most analyses, WHO grade III and 1V tumors are not analyzed separately.
  • The present analysis reports outcome after postoperative radiotherapy in patients with WHO grade III gliomas.
  • PATIENTS AND METHODS: Between January 1988 and January 2007, 127 patients with WHO grade III tumors were treated with radiotherapy; the histological classification was pure astrocytoma in 104 patients, oligoastrocytoma in 12 and pure oligodendroglioma in 11 patients.
  • After the primary diagnosis, a biopsy had been performed in 72 patients; subtotal and total resections were performed in 37 and 18 patients, respectively.
  • Median overall survival was 7 months for patients with anaplastic astrocytomas, 44 months for patients with mixed tumors, and 47 months for those with pure oligodendrogliomas.
  • CONCLUSION: Patients with WHO grade III anaplastic astrocytomas, oligodendrogliomas and oligoastrocytomas show favorable overall survival after postoperative radiotherapy compared with glioblastoma patients and should therefore be analyzed separately.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / radiotherapy. Glioma / pathology. Glioma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / pathology. Astrocytoma / radiotherapy. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Male. Middle Aged. Oligodendroglioma / pathology. Oligodendroglioma / radiotherapy. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Time Factors. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19688970.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


80. Bäcklund LM, Nilsson BR, Liu L, Ichimura K, Collins VP: Mutations in Rb1 pathway-related genes are associated with poor prognosis in anaplastic astrocytomas. Br J Cancer; 2005 Jul 11;93(1):124-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutations in Rb1 pathway-related genes are associated with poor prognosis in anaplastic astrocytomas.
  • Anaplastic astrocytoma (AA, WHO grade III) is, second to Glioblastoma, the most common and most malignant type of adult CNS tumour.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Genes, Retinoblastoma. Mutation


81. Liau CT, Wei KC, Tseng CK, Jung SM: Combination chemotherapy with carmustine and cisplatin followed by procarbazine, lomustine, and vincristine for adult high-grade astrocytoma. Chang Gung Med J; 2005 Jan;28(1):16-23
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination chemotherapy with carmustine and cisplatin followed by procarbazine, lomustine, and vincristine for adult high-grade astrocytoma.
  • BACKGROUND: We have reported that carmustine (BCNU) and cisplatin administered before, during, and after radiotherapy did not improve the survival of patients with high-grade astrocytomas and were associated with more serious toxicities than radiotherapy plus BCNU.
  • Of these, 20 had glioblastoma multiforme and 22 had anaplastic astrocytoma.
  • This combined modality treatment program was associated with reversible grade 3 to 4 hematological toxicity in 10 patients, with grade 3 ototoxicity in one patient and grade 2 neurotoxicity in one patient.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15804144.001).
  • [ISSN] 2072-0939
  • [Journal-full-title] Chang Gung medical journal
  • [ISO-abbreviation] Chang Gung Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; Q20Q21Q62J / Cisplatin; U68WG3173Y / Carmustine
  •  go-up   go-down


82. Parafiniuk D, Jezewski D, Nowacki P: [Malignant astrocytoma as a recurrance of astrocytoma II WHO after 13 years. Case report and literature review]. Ann Acad Med Stetin; 2010;56(2):45-50
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant astrocytoma as a recurrance of astrocytoma II WHO after 13 years. Case report and literature review].
  • They include slow growing tumors such as fibillary astrocytoma or very malignant glioblastoma multiforme.
  • The case which is being presented is of a forty nine year old woman operated in July 1997 because of a protoplasmic astrocytoma II WHO in the left frontal lobe.
  • Histopathology identified anaplastic astrocytoma III WHO.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Brain Neoplasms / surgery. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Adult. Astrocytoma. Female. Frontal Lobe. Humans. Reoperation. Seizures / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21473001.001).
  • [ISSN] 1427-440X
  • [Journal-full-title] Annales Academiae Medicae Stetinensis
  • [ISO-abbreviation] Ann Acad Med Stetin
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Poland
  •  go-up   go-down


83. Kano T, Ikota H, Wada H, Iwasa S, Kurosaki S: A case of an anaplastic ependymoma with gliosarcomatous components. Brain Tumor Pathol; 2009;26(1):11-7
Genetic Alliance. consumer health - Anaplastic Ependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of an anaplastic ependymoma with gliosarcomatous components.
  • The tumor was removed, and pathological studies revealed a cerebellar astrocytoma corresponding to World Health Organization grade II.
  • Pathological studies revealed a mixed glioblastoma multiforme and anaplastic ependymoma.
  • Subtotal removal of the tumor was performed; pathological studies revealed an anaplastic ependymoma with sarcomatous components.
  • [MeSH-minor] Adult. Astrocytoma / pathology. Astrocytoma / surgery. Female. Glial Fibrillary Acidic Protein / metabolism. Headache / etiology. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Neoplasm Recurrence, Local. Paraffin Embedding. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19408092.001).
  • [ISSN] 1861-387X
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein
  •  go-up   go-down


84. Holland H, Koschny T, Ahnert P, Meixensberger J, Koschny R: WHO grade-specific comparative genomic hybridization pattern of astrocytoma - a meta-analysis. Pathol Res Pract; 2010 Oct 15;206(10):663-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] WHO grade-specific comparative genomic hybridization pattern of astrocytoma - a meta-analysis.
  • To identify aberration profiles characteristic of World Health Organization (WHO) grade I, II, III, and IV astrocytoma, we performed a meta-analysis of detailed genome wide CGH data of all 467 cases published so far.
  • Low-grade astrocytoma has already demonstrated one characteristic of glioblastoma multiforme, gain of chromosome 7 with a hot spot at 7q32, but without loss of chromosome 10.
  • In anaplastic astrocytoma, a more complex aberration pattern emerges from diffuse genetic imbalances.
  • To quantify the gradual transition from WHO grade II-IV astrocytoma, we calculated the relative increase and decrease in frequency for each detected aberration of the tumor genome.
  • The most pronounced and diverse changes of genetic material occur at the virtual transition from low-grade to anaplastic astrocytoma.
  • Summing up, the expansion of the CGH results to the 850 GTG-band resolution enabled a meta-analysis to visualize WHO grade-specific aberration profiles in astrocytoma.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Chromosome Aberrations. Comparative Genomic Hybridization. Glioblastoma / genetics. World Health Organization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier GmbH. All rights reserved.
  • (PMID = 20570053.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] Germany
  •  go-up   go-down


85. Takaya S, Hashikawa K, Turkheimer FE, Mottram N, Deprez M, Ishizu K, Kawashima H, Akiyama H, Fukuyama H, Banati RB, Roncaroli F: The lack of expression of the peripheral benzodiazepine receptor characterises microglial response in anaplastic astrocytomas. J Neurooncol; 2007 Oct;85(1):95-103
ORBi (University of Liege). Free full Text at ORBi .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The lack of expression of the peripheral benzodiazepine receptor characterises microglial response in anaplastic astrocytomas.
  • We examined two anaplastic astrocytomas showing minimal contrast-enhancement and therefore little damage of the blood brain barrier to minimise the presence of blood borne macrophages within tumour tissue.
  • The expression profile of four anaplastic astrocytomas was also exploited and results were compared to the profile of eleven samples of normal temporal lobe and nine cases of PD.
  • [MeSH-major] Astrocytoma / metabolism. Astrocytoma / pathology. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Microglia / metabolism. Microglia / pathology. Receptors, GABA-A / biosynthesis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17520179.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U120085814
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Isoquinolines; 0 / RNA, Messenger; 0 / Radiopharmaceuticals; 0 / Receptors, GABA-A; YNF83VN1RL / PK 11195
  •  go-up   go-down


86. Barnholtz-Sloan JS, Williams VL, Maldonado JL, Shahani D, Stockwell HG, Chamberlain M, Sloan AE: Patterns of care and outcomes among elderly individuals with primary malignant astrocytoma. J Neurosurg; 2008 Apr;108(4):642-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of care and outcomes among elderly individuals with primary malignant astrocytoma.
  • OBJECT: This study was undertaken to evaluate the association between age at diagnosis, patterns of care, and outcome among elderly individuals with anaplastic astrocytoma (AA) and glioblastoma multiforme (GBM).
  • To facilitate gathering of prediagnosis comorbidity and postdiagnosis treatment information, only those individuals were included who had the same Medicare coverage for 6 months before and 12 months after diagnosis.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurosurg. 2012 Feb;116(2):355-6; discussion 356 [21942728.001]
  • [CommentIn] J Neurosurg. 2008 Apr;108(4):639-40 [18377239.001]
  • (PMID = 18377240.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K08 CA101954; United States / NCI NIH HHS / CA / K07-CA91849; United States / NCI NIH HHS / CA / K08-CA101954
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


87. Siker ML, Chakravarti A, Mehta MP: Should concomitant and adjuvant treatment with temozolomide be used as standard therapy in patients with anaplastic glioma? Crit Rev Oncol Hematol; 2006 Nov;60(2):99-111
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Should concomitant and adjuvant treatment with temozolomide be used as standard therapy in patients with anaplastic glioma?
  • While it seems intuitive to apply this regimen to patients with anaplastic gliomas which have traditionally been considered more chemosensitive, chemotherapy has not been shown to prolong life in patients with anaplastic gliomas.
  • Despite promising preclinical and early clinical results, there is currently not enough level 1 evidence to justify concomitant and adjuvant temozolomide as standard therapy for patients with newly diagnosed anaplastic gliomas.
  • Further investigation is needed to better define the role of chemotherapy in patients with anaplastic gliomas.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Carcinoma / radiotherapy. Dacarbazine / analogs & derivatives

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17027279.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Tumor Suppressor Protein p14ARF; 0 / Tumor Suppressor Proteins; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  • [Number-of-references] 93
  •  go-up   go-down


88. Postovsky S, Eran A, Weyl Ben Arush M: Unusual case of leptomeningeal dissemination of a diffuse pontine high-grade astrocytoma in a child. Pediatr Neurosurg; 2008;44(3):208-11
Genetic Alliance. consumer health - Diffuse Astrocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual case of leptomeningeal dissemination of a diffuse pontine high-grade astrocytoma in a child.
  • The histological diagnosis was anaplastic astrocytoma.
  • However, 3 months after completion of radiotherapy, the child developed widespread leptomeningeal dissemination of her disease and died 12 months after the initial diagnosis.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Stem Neoplasms / diagnosis. Meningeal Neoplasms / diagnosis. Pons / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18334845.001).
  • [ISSN] 1423-0305
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


89. Koga T, Morita A, Maruyama K, Tanaka M, Ino Y, Shibahara J, Louis DN, Reifenberger G, Itami J, Hara R, Saito N, Todo T: Long-term control of disseminated pleomorphic xanthoastrocytoma with anaplastic features by means of stereotactic irradiation. Neuro Oncol; 2009 Aug;11(4):446-51
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term control of disseminated pleomorphic xanthoastrocytoma with anaplastic features by means of stereotactic irradiation.
  • Pleomorphic xanthoastrocytoma (PXA) is a rare astrocytic neoplasm of the brain.
  • Some PXAs are accompanied by anaplastic features and are difficult to manage because of frequent recurrences that lead to early death.
  • We report a case of PXA with anaplastic features treated with stereotactic irradiation (STI) that resulted in long-term control of repeatedly recurring nodules throughout the neuraxis.
  • The tumor was resected and diagnosed as PXA with anaplastic features.
  • However, diffuse dissemination along the craniospinal axis eventually progressed, and she died 66 months after initial diagnosis.
  • STI may be an effective therapeutic tool for controlling nodular dissemination of PXA with anaplastic features.
  • [MeSH-major] Astrocytoma / surgery. Brain Neoplasms / surgery. Radiosurgery

  • Genetic Alliance. consumer health - Pleomorphic xanthoastrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Neurosurg. 1999 Oct;13(5):516-9 [10627788.001]
  • [Cites] Histopathology. 2008 Jan;52(2):183-93 [18184267.001]
  • [Cites] Childs Nerv Syst. 2001 Sep;17(9):563-6 [11585332.001]
  • [Cites] Ultrastruct Pathol. 2001 Nov-Dec;25(6):469-78 [11783911.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Dec;61(12):1092-9 [12484572.001]
  • [Cites] Childs Nerv Syst. 2004 Feb;20(2):119-22 [14669022.001]
  • [Cites] Cancer. 1979 Nov;44(5):1839-52 [498051.001]
  • [Cites] Neurosurgery. 1985 May;16(5):703-6 [4000446.001]
  • [Cites] Neurosurgery. 1988 Feb;22(2):422-7 [3352896.001]
  • [Cites] J Neurosurg. 1989 Mar;70(3):463-8 [2644402.001]
  • [Cites] Acta Neuropathol. 1989;78(6):585-93 [2816300.001]
  • [Cites] Clin Neuropathol. 1993 Mar-Apr;12(2):97-101 [8477554.001]
  • [Cites] Acta Neuropathol. 1994;87(3):225-32 [8009954.001]
  • [Cites] Neurosurg Rev. 1996;19(1):13-6 [8738360.001]
  • [Cites] Acta Neuropathol. 1996;91(3):293-7 [8834542.001]
  • [Cites] Childs Nerv Syst. 1997 Jan;13(1):50-6 [9083703.001]
  • [Cites] J Neurosurg Sci. 1998 Sep;42(3):153-7 [10192056.001]
  • [Cites] Cancer. 1999 May 1;85(9):2033-45 [10223246.001]
  • [Cites] Acta Neurochir (Wien). 2006 Jan;148(1):67-71; discussion 71 [15912255.001]
  • [Cites] Neurosurgery. 2006 Apr;58(4):674-85; discussion 674-85 [16575331.001]
  • [Cites] Neurosurgery. 2006 Jun;58(6):1081-9; discussion 1081-9 [16723887.001]
  • [Cites] J Neurol Sci. 2007 Jan 31;252(2):144-53 [17189643.001]
  • [Cites] Oncogene. 2007 Feb 15;26(7):1088-97 [16909113.001]
  • [Cites] Neuro Oncol. 2001 Jul;3(3):184-92 [11465399.001]
  • (PMID = 19164434.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2743225
  •  go-up   go-down


90. Miyajima Y, Sato Y, Oka H, Utsuki S, Kondo K, Tanizaki Y, Nagashio R, Tsuchiya B, Okayasu I, Fujii K: Prognostic significance of nuclear DJ-1 expression in astrocytoma. Anticancer Res; 2010 Jan;30(1):265-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of nuclear DJ-1 expression in astrocytoma.
  • Twenty-nine formalin-fixed and paraffin-embedded glioblastomas (grade IV), 21 anaplastic astorocytomas (grade III), and 14 diffuse astrocytomas (grade II) were immunohistochemically studied to identify the expression of DJ-1 protein.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Oncogene Proteins / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20150646.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Oncogene Proteins; 0 / PARK7 protein, human
  •  go-up   go-down


91. Matsuoka H, Maruyama D, Takegami T, Hamasaki T, Kakita K, Mineura K: [A case of pontine astrocytoma with unusual neuroimaging features]. No Shinkei Geka; 2009 Oct;37(10):1001-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of pontine astrocytoma with unusual neuroimaging features].
  • The patient underwent stereotactic biopsy of the left thalamic tumor, under general anesthesia, and the histological diagnosis was anaplastic astrocytoma.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Stem Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19882961.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


92. Molina Saera J, Segura Huerta A, Palomar Abad L, Giménez Ortiz A, Ponce Lorenzo J, Reynés Muntaner G: [Extra-cranial anaplastic oligoastrocytoma development from a low-grade glioma]. Clin Transl Oncol; 2005 Apr;7(3):127-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Extra-cranial anaplastic oligoastrocytoma development from a low-grade glioma].
  • [Transliterated title] Afectación extracraneal de oligoastrocitoma anaplásico desarrollado sobre un glioma de bajo grado.
  • Oligodendrogliomas are primary brain tumours derived from oligodendroglial cells, or precursors, and represent 2%-5% of brain tumours.
  • This type of glioma has a favourable prognosis compared to other brain tumours.
  • We present a patient who had received treatment previously for a lowgrade glioma and who subsequently developed an anaplastic oligoastrocytoma in the same zone together with skull and extra-cranial involvement in the disease progression.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Brain Neoplasms / surgery. Glioma / surgery. Neoplasms, Second Primary / pathology. Skull Neoplasms / pathology. Temporal Bone. Temporal Lobe

  • Genetic Alliance. consumer health - Glioma.
  • Genetic Alliance. consumer health - Anaplastic Oligoastrocytoma.
  • Genetic Alliance. consumer health - Oligoastrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15899221.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


93. Niizuma K, Fujimura M, Kumabe T, Tominaga T: Malignant transformation of high-grade astrocytoma associated with neurocysticercosis in a patient with Turcot syndrome. J Clin Neurosci; 2007 Jan;14(1):53-5
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of high-grade astrocytoma associated with neurocysticercosis in a patient with Turcot syndrome.
  • A 45-year-old woman with anaplastic astrocytoma was clinically diagnosed with Turcot syndrome, and subsequently developed simultaneous neurocysticercosis and malignant transformation to glioblastoma.
  • Histological examination of surgical specimens revealed neurocysticercosis between the normal brain tissue and glioblastoma.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Cell Transformation, Neoplastic / pathology. Glioblastoma / pathology. Neurocysticercosis / pathology

  • Genetic Alliance. consumer health - Turcot syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17138070.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


94. Moulding HD, Friedman DP, Curtis M, Kenyon L, Flanders AE, Paek SH, Andrews DW: Revisiting anaplastic astrocytomas I: an expansive growth pattern is associated with a better prognosis. J Magn Reson Imaging; 2008 Dec;28(6):1311-21
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Revisiting anaplastic astrocytomas I: an expansive growth pattern is associated with a better prognosis.
  • PURPOSE: To study whether anaplastic astrocytomas that are nonenhancing and/or well-circumscribed (expansive) are associated with a better prognosis.
  • MATERIALS AND METHODS: We retrospectively identified 59 patients with pathologically confirmed World Health Organizaiton (WHO) grade III anaplastic astrocytoma who underwent craniotomy at our institution from 1995 through 2006.
  • CONCLUSION: Circumscribed growth in histologically proven anaplastic astrocytoma, which has not been emphasized in past studies, has a considerable survival advantage.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Magnetic Resonance Imaging / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 19025897.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


95. Yi L, Zhou ZH, Ping YF, Chen JH, Yao XH, Feng H, Lu JY, Wang JM, Bian XW: Isolation and characterization of stem cell-like precursor cells from primary human anaplastic oligoastrocytoma. Mod Pathol; 2007 Oct;20(10):1061-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolation and characterization of stem cell-like precursor cells from primary human anaplastic oligoastrocytoma.
  • Oligoastrocytoma is the most common brain mixed glioma composed of mixed cells of oligodendroglial and astrocytic phenotypes.
  • Here, tumor stem cell-like precursors were identified from primary human anaplastic oligoastrocytomas by labeling of the tumor sections with nestin and CD133.
  • This study revealed for the first time that anaplastic human oligoastrocytomas contained stem cell-like precursors, which exhibit neural stem cell properties with tumorigenicity.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Neoplastic Stem Cells / pathology
  • [MeSH-minor] Animals. Antigens, CD / analysis. Biomarkers, Tumor / analysis. Brain / pathology. Fluorescent Antibody Technique, Indirect. Glycoproteins / analysis. Humans. Intermediate Filament Proteins / analysis. Magnetic Resonance Imaging. Mice. Mice, Nude. Neoplasm Transplantation. Nerve Tissue Proteins / analysis. Nestin. Peptides / analysis. Spheroids, Cellular / chemistry. Spheroids, Cellular / pathology. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Anaplastic Oligoastrocytoma.
  • Genetic Alliance. consumer health - Oligoastrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17660801.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nes protein, mouse; 0 / Nestin; 0 / Peptides
  •  go-up   go-down


96. van den Boom J, Wolter M, Blaschke B, Knobbe CB, Reifenberger G: Identification of novel genes associated with astrocytoma progression using suppression subtractive hybridization and real-time reverse transcription-polymerase chain reaction. Int J Cancer; 2006 Nov 15;119(10):2330-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of novel genes associated with astrocytoma progression using suppression subtractive hybridization and real-time reverse transcription-polymerase chain reaction.
  • To identify novel genes involved in glioma progression we performed suppression subtractive hybridization combined with cDNA array analysis on 4 patients with primary low-grade gliomas of World Health Organization (WHO) grade II that recurred as secondary glioblastomas (WHO grade IV).
  • Eight genes showing differential expression between primary and recurrent tumors in 3 of the 4 patients were selected for further analysis using real-time reverse transcription-PCR on a series of 10 pairs of primary low-grade and recurrent high-grade gliomas as well as 42 astrocytic gliomas of different WHO grades.
  • These analyses revealed that 5 genes, i.e., AMOG (ATP1B2, 17p13.1), APOD (3q26.2-qter), DMXL1 (5q23.1) DRR1 (TU3A, 3p14.2) and PSD3 (KIAA09428/HCA67/EFA6R, 8p22), were expressed at significantly lower levels in secondary glioblastomas as compared to diffuse astrocytomas of WHO grade II.
  • Sequencing of sodium bisulfite-modified DNA demonstrated AMOG promoter hypermethylation in the glioma cell lines and 1 primary anaplastic astrocytoma with low AMOG expression.
  • [MeSH-major] Adenosine Triphosphatases / genetics. Astrocytoma / genetics. Brain Neoplasms / genetics. Cation Transport Proteins / genetics. Cell Adhesion Molecules, Neuronal / genetics. Gene Silencing. Nucleic Acid Hybridization. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16865689.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / APOD protein, human; 0 / ATP1B2 protein, human; 0 / Antimetabolites, Antineoplastic; 0 / Apolipoproteins; 0 / Apolipoproteins D; 0 / Biomarkers, Tumor; 0 / Cation Transport Proteins; 0 / Cell Adhesion Molecules, Neuronal; 0 / DMXL1 protein, human; 0 / FAM107A protein, human; 0 / Glycoproteins; 0 / Hydroxamic Acids; 0 / Membrane Transport Proteins; 0 / Nerve Tissue Proteins; 0 / Nuclear Proteins; 0 / PSD protein, human; 0 / Protein Synthesis Inhibitors; 0 / Proteins; 3X2S926L3Z / trichostatin A; 776B62CQ27 / decitabine; EC 3.5.1.98 / Histone Deacetylases; EC 3.5.1.98 / histone deacetylase 3; EC 3.6.1.- / Adenosine Triphosphatases; M801H13NRU / Azacitidine
  •  go-up   go-down


97. Freitas MR, de Muzio SD, Pessoa RC, Stávale JN, Borges LR, Malheiros SM: [Diffuse bone marrow metastasis in cerebellar high-grade astrocytoma. A case report]. Rev Neurol; 2009 Mar 1-15;48(5):242-4
Genetic Alliance. consumer health - Diffuse Astrocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diffuse bone marrow metastasis in cerebellar high-grade astrocytoma. A case report].
  • [Transliterated title] Metastasis difusa de la medula osea en un astrocitoma cerebeloso de alto grado. Un caso clinico.
  • INTRODUCTION: Cerebellar high-grade astrocytoma is uncommon.
  • CASE REPORT: A 46 year-old man with cerebellar anaplastic astrocytoma who developed pancytopenia due to extensive bone marrow metastases.
  • CONCLUSION: Extraneural metastases of brain gliomas are rare and the spread to the bone marrow confers an extremely poor prognosis for these patients.
  • [MeSH-major] Astrocytoma / pathology. Bone Marrow Neoplasms / secondary. Cerebellar Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19263392.001).
  • [ISSN] 1576-6578
  • [Journal-full-title] Revista de neurologia
  • [ISO-abbreviation] Rev Neurol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


98. Jayawardena S, Sooriabalan D, Indulkar S, Kim HH, Matin A, Maini A: Regression of grade III astrocytoma during the treatment of CML with imatinib mesylate. Am J Ther; 2006 Sep-Oct;13(5):458-9
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regression of grade III astrocytoma during the treatment of CML with imatinib mesylate.
  • The cells that demonstrate the greatest degree of anaplasia are used to determine the histologic grade of the tumor.
  • The mean age of survival are approximately 10 years from the time of diagnosis for pilocystic astrocytomas (World Health Organization grade I), more than 5 years for patients with low-grade diffuse astrocytomas (WHO grade II), 2 to 5 years for those with anaplastic astrocytomas (WHO grade III), and less than 1 year for patients with glioblastoma (WHO grade IV).
  • The treatment is a combination of surgery, radiation, and chemotherapy depending of the grade of astrocytoma.
  • We present a case of 31-year-old man with grade III astrocytoma with subsequent chronic myelogenous leukemia treated with imatinib mesylate as part of his chronic myelogenous leukemia treatment failing to show recurrence of the astrocytoma 10 years after standard treatment for astrocytoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Leukemia, Myeloid, Acute / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16988542.001).
  • [ISSN] 1075-2765
  • [Journal-full-title] American journal of therapeutics
  • [ISO-abbreviation] Am J Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


99. Reddy PS, Umesh S, Thota B, Tandon A, Pandey P, Hegde AS, Balasubramaniam A, Chandramouli BA, Santosh V, Rao MR, Kondaiah P, Somasundaram K: PBEF1/NAmPRTase/Visfatin: a potential malignant astrocytoma/glioblastoma serum marker with prognostic value. Cancer Biol Ther; 2008 May;7(5):663-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PBEF1/NAmPRTase/Visfatin: a potential malignant astrocytoma/glioblastoma serum marker with prognostic value.
  • Malignant astrocytomas comprise anaplastic astrocytoma (AA; grade III) and Glioblastoma (GBM; grade IV).
  • Further validation using real time RT-qPCR on an independent set of tumor samples (n=91) and normal brain samples (n=9), GBM specific higher expression of PBEF1 was confirmed.
  • We carried out ELISA analysis on serum samples of astrocytoma patients to determine whether this protein levels would correlate with the presence of tumor and tumor grade.
  • Statistical analysis of these data indicates that in patients with astrocytoma, serum PBEF1 levels correlate with tumor grade and is highest in GBM.
  • Thus, we have identified PBEF1 as a potential malignant astrocytoma serum marker and prognostic indicator among GBMs.
  • [MeSH-major] Astrocytoma / metabolism. Biomarkers, Tumor. Brain / metabolism. Brain Neoplasms / metabolism. Cytokines / physiology. Gene Expression Regulation, Neoplastic. Glioblastoma / metabolism. Nicotinamide Phosphoribosyltransferase / metabolism

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18728403.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cytokines; 0 / Tumor Suppressor Protein p53; EC 2.4.2.12 / Nicotinamide Phosphoribosyltransferase; EC 2.4.2.12 / nicotinamide phosphoribosyltransferase, human
  •  go-up   go-down


100. Sathornsumetee S, Cao Y, Marcello JE, Herndon JE 2nd, McLendon RE, Desjardins A, Friedman HS, Dewhirst MW, Vredenburgh JJ, Rich JN: Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol; 2008 Jan 10;26(2):271-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan.
  • Tumor specimens collected at the time of diagnosis were available for further pathologic studies in 45 patients (75%).
  • RESULTS: Of 45 patients, 27 patients had glioblastoma multiforme, and 18 patients had anaplastic astrocytoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3714-21 [15897568.001]
  • [Cites] N Engl J Med. 2005 Nov 10;353(19):2012-24 [16282176.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):217-27 [16365183.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):473-7 [16428489.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):67-78 [16443950.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):727-35 [16418497.001]
  • [Cites] Neuro Oncol. 2006 Apr;8(2):189-93 [16533878.001]
  • [Cites] Neurology. 2006 Apr 25;66(8):1258-60 [16636248.001]
  • [Cites] Nature. 2006 May 25;441(7092):437-43 [16724055.001]
  • [Cites] Nat Rev Cancer. 2006 Aug;6(8):626-35 [16837971.001]
  • [Cites] Nat Clin Pract Neurol. 2006 May;2(5):232-3 [16932555.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5260-4 [17000656.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]
  • [Cites] Hum Pathol. 2007 Apr;38(4):629-38 [17367605.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 15;97(12):880-7 [15956649.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4722-9 [17947719.001]
  • [Cites] Cancer Metastasis Rev. 2007 Jun;26(2):299-310 [17415526.001]
  • [Cites] Nat Rev Neurosci. 2007 Aug;8(8):610-22 [17643088.001]
  • [Cites] J Clin Oncol. 2007 Jun 20;25(18):2601-6 [17577040.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3835-44 [17440098.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] J Histochem Cytochem. 2000 Aug;48(8):1103-10 [10898803.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2742-6 [12782577.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6130-4 [14559790.001]
  • [Cites] Mol Cell Biol. 2003 Dec;23(24):9361-74 [14645546.001]
  • [Cites] Cell Cycle. 2004 Feb;3(2):164-7 [14712082.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):21-7 [14769136.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1516-25 [10334539.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • (PMID = 18182667.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS054276; United States / NCI NIH HHS / CA / R01 CA116659; United States / NCI NIH HHS / CA / CA116659; United States / NINDS NIH HHS / NS / K02 NS047409; United States / NINDS NIH HHS / NS / NS047409; United States / NINDS NIH HHS / NS / R01 NS054276
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factor A; 0H43101T0J / irinotecan; 2S9ZZM9Q9V / Bevacizumab; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ NIHMS508913; NLM/ PMC3930173
  •  go-up   go-down






Advertisement